VIOLIN: Vaccine Investigation and Online Information Network

Herpes simplex virus type 1 and 2

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. gD (Other)
2. gB (Protective antigen)
3. ICP27 (Protective antigen)
4. ICP27 from Herpes simplex virus type 2 (Protective antigen)
5. UL27 (Protective antigen)
6. UL27 from Herpes simplex virus type 1 (Protective antigen)
7. UL44 from HSV-1 (Protective antigen)
8. UL44 from HSV-2 (Protective antigen)
9. US4 (Protective antigen)
10. US5 (Protective antigen)
11. US6 (Protective antigen)
12. US7 (Protective antigen)
13. US8 (Protective antigen, Virmugen)
14. gD (Virmugen)
15. gH (Virmugen)
16. ICP0 (Virmugen)
17. TK (Virmugen)
18. UL29 (Virmugen)
Vaccine Related Host Genes
1. IgG
2. Ighv1-9
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

10298

2. Disease:

Herpes

3. Introduction

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family, Herpesviridae, that infect humans. Both HSV-1 and -2 are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with a scab characteristic of herpetic disease. However, as neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body for the life of the carrier by becoming latent and hiding from the immune system in the cell bodies of nerves. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. In an outbreak, the virus in a nerve cell becomes active and is transported via the nerve's axon to the skin, where virus replication and shedding occur and cause new sores.
There is no known cure for HSV infection, but treatments can reduce the likelihood of viral shedding and spread (Wiki: Herpes simplex virus).

4. Microbial Pathogenesis

In the case of a herpes virus, initial interactions occur when a viral envelope glycoprotein called glycoprotein C (gC) binds to a cell surface particle called heparan sulfate. A second glycoprotein, glycoprotein D (gD), binds specifically to at least one of three known entry receptors. These include herpesvirus entry mediator(HVEM), nectin-1 and 3-O sulfated heparan sulfate. The receptor provides a strong, fixed attachment to the host cell. These interactions bring the membrane surfaces into mutual proximity and allow for other glycoproteins embedded in the viral envelope to interact with other cell surface molecules. HSVs may persist in a quiescent but persistent form known as latent infection, notably in neural ganglia. HSV-1 tends to reside in the trigeminal ganglia, while HSV-2 tends to reside in the sacral ganglia, but note that these are tendencies only, not fixed behavior (Wiki: Herpes simplex virus).

5. Host Ranges and Animal Models

HSV-1 and HSV-2 infect humans and mice are used as a model of protection in vaccine studies (Nass et al., 1998).

6. Host Protective Immunity

HSV evades the immune system through interference with MHC class I presentation of antigen on the cell surface. This is achieved through blockade of the TAP transporter induced by the secretion of ICP-47 by HSV. TAP maintains the integrity of the MHC class I molecule before it is transported via the golgi apparatus for recognition by CD8+ CTLs on the cell surface. ICP-47 disrupts this integrity, preventing the capture of cytosolic proteins for CTL recognition and thus evades CTL destruction (Wiki: Herpes simplex virus).

II. Vaccine Related Pathogen Genes

1. gB

Gene Name : gB
Sequence Strain (Species/Organism) : Human herpesvirus 1 strain KOS
NCBI Protein GI : 1353200
Other Database IDs : CDD:223014
Taxonomy ID : 10306
Gene Strand (Orientation) : ?
Protein Name : Envelope glycoprotein B
Protein pI : 7.97
Protein Weight : 94956.45
Protein Length : 1006
Protein Note : gB

Protein Sequence : Show Sequence

>sp|P06437.2|GB_HHV1K RecName: Full=Envelope glycoprotein B; Short=gB; Flags: Precursor
MHQGAPSWGRRWFVVWALLGLTLGVLVASAAPTSPGTPGVAAATQAANGGPATPAPPPLGAAPTGDPKPK
KNKKPKNPTPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPPTGATVVQFEQPRRCPTRPEGQ
NYTEGIAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRST
AKYVRNNLETTAFHRDDHETDMELKPANAATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARS
VYPYDEFVLATGDFVYMSPFYGYREGSHTEHTTYAADRFKQVDGFYARDLTTKARATAPTTRNLLTTPKF
TVAWDWVPKRPSVCTMTKWQEVDEMLRSEYGGSFRFSSDAISTTFTTNLTEYPLSRVDLGDCIGKDARDA
MDRIFARRYNATHIKVGQPQYYQANGGFLIAYQPLLSNTLAELYVREHLREQSRKPPNPTPPPPGASANA
SVERIKTTSSIEFARLQFTYNHIQRHVNDMLGRVAIAWCELQNHELTLWNEARKLNPNAIASVTVGRRVS
ARMLGDVMAVSTCVPVAADNVIVQNSMRISSRPGACYSRPLVSFRYEDQGPLVEGQLGENNELRLTRDAI
EPCTVGHRRYFTFGGGYVYFEEYAYSHQLSRADITTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLL
DYTEVQRRNQLHDLRFADIDTVIHADANAAMFAGLGAFFEGMGDLGRAVGKVVMGIVGGVVSAVSGVSSF
MSNPFGALAVGLLVLAGLAAAFFAFRYVMRLQSNPMKALYPLTTKELKNPTNPDASGEGEEGGDFDEAKL
AEAREMIRYMALVSAMERTEHKAKKKGTSALLSAKVTDMVMRKRRNTNYTQVPNKDGDADEDDL

Molecule Role : Protective antigen
Related Vaccine(s): Herpes simplex virus DNA vaccine pCI-gB encoding gB , pRP-RSV-HSV-1-gB

2. gD

Gene Name : gD
NCBI Protein GI : 19548971
3D structure: PDB ID : 1L2G
Other Database IDs : CDD:177571
CDD:186820
Taxonomy ID : 10298
Gene Strand (Orientation) : ?
Protein Name : glycoprotein D
Protein Length : 394
Protein Note : envelope glycoprotein D; Provisional

Protein Sequence : Show Sequence

>gi|19548971|gb|AAL90884.1|AF487902_1 glycoprotein D [human herpesvirus 1]
MGGAAARLGAVILFVVIVGLHGVRGKYALADASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLP
NPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVMEY
TECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
KGSCKYTLPLRIPPSACLSPQAYQQGVTVDSIGMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPP
ELSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNNMGLIAGAVGGS
LLAALVICGIVYWMHRRTRKAPKPIRLPHIREDDQPSSHQPLFY

Molecule Role : Virmugen
Molecule Role Annotation : KOS-gDA3C is attenuated with mutations in gD gene in causing skin lesions at the inoculation and zosteriform sites, yet it is as effective as rKOS-gDA3C in protecting mice against HSV-1 challenge (Awasthi et al., 2008).
Related Vaccine(s): Herpes simplex virus 1 gD mutant vaccine , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21

3. gD

Gene Name : gD
Sequence Strain (Species/Organism) : Human herpesvirus 2
NCBI Gene ID : 1487358
NCBI Protein GI : 9629336
Locus Tag : HHV2gp69
Genbank Accession : AY779751
Protein Accession : NP_044536
Taxonomy ID : 10310
Gene Starting Position : 141015
Gene Ending Position : 143591
Gene Strand (Orientation) : +
Protein Name : envelope glycoprotein D
Protein pI : 7.84
Protein Weight : 40611.38
Protein Length : 393
Protein Note : gD family

DNA Sequence : Show Sequence

>gi|9629267:141015-143591 Human herpesvirus 2, complete genome
CATGGGGCGTTTGACCTCCGGCGTCGGGACGGCGGCCCTGCTAGTTGTCGCGGTGGGACTCCGCGTCGTC
TGCGCCAAATACGCCTTAGCAGACCCCTCGCTTAAGATGGCCGATCCCAATCGATTTCGCGGGAAGAACC
TTCCGGTTTTGGACCAGCTGACCGACCCCCCCGGGGTGAAGCGTGTTTACCACATTCAGCCGAGCCTGGA
GGACCCGTTCCAGCCCCCCAGCATCCCGATCACTGTGTACTACGCAGTGCTGGAACGTGCCTGCCGCAGC
GTGCTCCTACATGCCCCATCGGAGGCCCCCCAGATCGTGCGCGGGGCTTCGGACGAGGCCCGAAAGCACA
CGTACAACCTGACCATCGCCTGGTATCGCATGGGAGACAATTGCGCTATCCCCATCACGGTTATGGAATA
CACCGAGTGCCCCTACAACAAGTCGTTGGGGGTCTGCCCCATCCGAACGCAGCCCCGCTGGAGCTACTAT
GACAGCTTTAGCGCCGTCAGCGAGGATAACCTGGGATTCCTGATGCACGCCCCCGCCTTCGAGACCGCGG
GTACGTACCTGCGGCTAGTGAAGATAAACGACTGGACGGAGATCACACAATTTATCCTGGAGCACCGGGC
CCGCGCCTCCTGCAAGTACGCTCTCCCCCTGCGCATCCCCCCGGCAGCGTGCCTCACCTCGAAGGCCTAC
CAACAGGGCGTGACGGTCGACAGCATCGGGATGCTACCCCGCTTTATCCCCGAAAACCAGCGCACCGTCG
CCCTATACAGCTTAAAAATCGCCGGGTGGCACGGCCCCAAGCCCCCGTACACCAGCACCCTGCTGCCGCC
GGAGCTGTCCGACACCACCAACGCCACGCAACCCGAACTCGTTCCGGAAGACCCCGAGGACTCGGCCCTC
TTAGAGGATCCCGCCGGGACGGTGTCTTCGCAGATCCCCCCAAACTGGCACATCCCGTCGATCCAGGACG
TCGCGCCGCACCACGCCCCCGCCGCCCCCAGCAACCCGGGCCTGATCATCGGCGCGCTGGCCGGCAGTAC
CCTGGCGGTGCTGGTCATCGGCGGTATTGCGTTTTGGGTACGCCGCCGCGCTCAGATGGCCCCCAAGCGC
CTACGTCTCCCCCACATCCGGGATGACGACGCGCCCCCCTCGCACCAGCCATTGTTTTACTAGAGGAGTT
TCCCCGCTCCCGTGTACCTCTGGGCCCGTGTGGGAGGGTGGCTGGGGTATTTGGGTGGGACTTGGACTCC
GCATAAAGGGAGTCTCGAAGGAGGGAAACTAGGACAGTTCATAGGCCGGGAGCGTGGGGCGCGCACCGCT
GTCCCGACGATTAGCCACCGCGCCCACAGCCACCTCGACCCGTCCGATCCCGGTATGCCCGGCCGCTCGC
TGCAGGGCCTGGCGATCCTGGGCCTGTGGGTCTGCGCCACCGGCCTGGTCGTCCGCGGCCCCACGGTCAG
TCTGGTCTCAGACTCACTCGTGGATGCCGGGGCCGTGGGGCCCCAGGGCTTCGTGGAAGAGGACCTGCGT
GTTTTCGGGGAGCTTCATTTTGTGGGGGCCCAGGTCCCCCATACAAACTACTACGACGGCATCATCGAGC
TGTTTCACTACCCCCTGGGGAACCACTGCCCCCGCGTTGTACACGTGGTCACACTGACCGCATGCCCCCG
CCGCCCCGCCGTGGCGTTCACCTTGTGTCGCTCGACGCACCACGCCCACAGCCCCGCCTATCCGACCCTG
GAGCTGGGTCTGGCGCGGCAGCCGCTTCTGCGGGTTCGAACGGCAACGCGCGACTATGCCGGTCTGTATG
TCCTGCGCGTATGGGTCGGCAGCGCGACGAACGCCAGCCGGTTTGTTTTGGGGGTGGCGCTCTCTGCCAA
CGGGACGTTTGTGTATAACGGCTCGGACTACGGCTCCTGCGATCCGGCGCAGCTTCCCTTTTCGGCCCCG
CGCCTGGGACCCTCGAGCGTATACACCCCCGGAGCCTCCCGACCCACCCCTCCACGGACAACGACACCCC
CGTCCTCCCCCCGAGACCCGACCCCCGCCCCCGGGGACACAGGGACGCCCGCGCCCGCGAGCGGCGAGAT
AGCCCCGCCCAATTCCACGCGATCGGCCAGCGAATCGAGACACAGGCTAACCGTAGCCCAGGTAATCCAG
ATCGCCATACCGGCGTCCATCATCGCCTTTGTGTTTCTGGGCAGCTGTATCTGCTTCATCCATAGATGCC
AGCGCCGATACAGGCGCCCCCGCGGCCAGATTTACAACCCCGGGGGCGTTTCCTGCGCGGTCAACGAGGC
GGCCATGGCCCGCCTCGGAGCCGAGCTGCGATCCCACCCAAACACCCCCCCCAAACCCCGACGCCGTTCG
TCGTCGTCCACGACCATGCCTTCCCTAACGTCGATAGCTGAGGAATCGGAGCCAGGTCCAGTCGTGCTGC
TGTCCGTCAGTCCTCGGCCCCGCAGTGGCCCGACGGCCCCCCAAGAGGTCTAGGTCCAAGCGGGCCGTTC
GGCAGGCCCGCCCCACCGCCCCCATCGTGGTTATTTCCCCCCCCCCCCCCCCAATAA

Protein Sequence : Show Sequence

>gi|9629336|ref|NP_044536.1| envelope glycoprotein D [Human herpesvirus 2]
MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLE
DPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEY
TECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPP
ELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGST
LAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY

Molecule Role : Other
Related Vaccine(s): Herpes Simplex Virus 2 DNA Vaccine encoding gD , Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L , Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2 , Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis , Herpes simplex virus DNA vaccine gD-2 encoding gD , HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70 , rOka-gD2- HSV-2

4. gH

Gene Name : gH
NCBI Protein GI : 138315
Other Database IDs : CDD:177579
Taxonomy ID : 10299
Gene Strand (Orientation) : ?
Protein Name : Envelope glycoprotein H
Protein Length : 838
Protein Note : envelope glycoprotein H; Provisional

Protein Sequence : Show Sequence

>gi|138315|sp|P06477.1|GH_HHV11 RecName: Full=Envelope glycoprotein H; Short=gH; Flags: Precursor
MGNGLWFVGVIILGVAWGQVHDWTEQTDPWFLDGLGMDRMYWRDTNTGRLWLPNTPDPQKPPRGFLAPPD
ELNLTTASLPLLRWYEERFCFVLVTTAEFPRDPGQLLYIPKTYLLGRPPNASLPAPTTVEPTAQPPPSVA
PLKGLLHNPAASVLLRSRAWVTFSAVPDPEALTFPRGDNVATASHPSGPRDTPPPRPPVGARRHPTTELD
ITHLHNASTTWLATRGLLRSPGRYVYFSPSASTWPVGIWTTGELVLGCDAALVRARYGREFMGLVISMHD
SPPVEVMVVPAGQTLDRVGDPADENPPGALPGPPGGPRYRVFVLGSLTRADNGSALDALRRVGGYPEEGT
NYAQFLSRAYAEFFSGDAGAEQGPRPPLFWRLTGLLATSGFAFVNAAHANGAVCLSDLLGFLAHSRALAG
LAARGAAGCAADSVFFNVSVLDPTARLQLEARLQHLVAEILEREQSLALHALGYQLAFVLDSPSAYDAVA
PSAAHLIDALYAEFLGGRVLTTPVVHRALFYASAVLRQPFLAGVPSAVQRERARRSLLIASALCTSDVAA
ATNADLRTALARADHQKTLFWLPDHFSPCAASLRFDLDESVFILDALAQATRSETPVEVLAQQTHGLAST
LTRWAHYNALIRAFVPEASHRCGGQSANVEPRILVPITHNASYVVTHSPLPRGIGYKLTGVDVRRPLFLT
YLTATCEGSTRDIESKRLVRTQNQRDLGLVGAVFMRYTPAGEVMSVLLVDTDNTQQQIAAGPTEGAPSVF
SSDVPSTALLLFPNGTVIHLLAFDTQPVAAIAPGFLAASALGVVMITAALAGILKVLRTSVPFFWRRE

Molecule Role : Virmugen
Molecule Role Annotation : A gH mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 (Farrell et al., 1994).
Related Vaccine(s): Herpes simplex virus 1 gH mutant vaccine

5. ICP0

Gene Name : ICP0
Sequence Strain (Species/Organism) : Human herpesvirus 2
NCBI Gene ID : 1487289
NCBI Protein GI : 109676722
Locus Tag : HHV2gp61
Genbank Accession : Z86099
Protein Accession : NP_044528
Taxonomy ID : 10310
Gene Starting Position : 121626
Gene Ending Position : 124946
Gene Strand (Orientation) : -
Protein Name : ubiquitin E3 ligase ICP0
Protein pI : 8.18
Protein Weight : 77292.34
Protein Length : 824

DNA Sequence : Show Sequence

>gi|9629267:121626-124946 Human herpesvirus 2, complete genome
CTTTATTGTAAAATTTTTATAAATATAAAGTTTTTTTTTTCCTCAAGTTTTCAACAAGGCCAGAAAGTCC
ATAACAAAATGCTGGTGTGTGTTGCTGTTCGGGGCCGTGTCCGTCCCCCCCCCCCACTCCCACCCCCACT
TCCTGTCTCCTCCCCGTCTTTCCCCCCCCCCACCTCCCCCTGCCCCCGAGGCGCCTCGGCCGGTGGTCCG
GTGGGGGGCGGCTTCCTTCGGGCAGCAAGCCGAGTGTTAGCTCCCCCTACTCCCCGTGGCCCGCGGGGGC
GTCGCCGGCCGGCGCGGGCGCGCCCTGCTCCCGAGACCACGGGTGGCGCGACCGGAGGCCGTGGAAGTCC
AGCGCGCCCACCAGGGTGCCCTGGTCAAAGAGCATGTTGCCCACCGGGGTCATCCAGAGGCTGTTCCACT
CCGACGCGGGGGGCGTCGGGTAGTCGGGGGGCCTCACGCAGTTGCGCGCGTGCTCGGGGAGCAGGGTGCG
GCGGCTCCACGCGGGGGCCGCGGCCCGCAGCAGGTCCGCCACGTTCCCCGTCTGGTCCACGAGGACCACG
TAGGCCCCTATGTGGCCCGTCTCCATGTCCAGGACGGGCAGGCAGTCCCCCGTGACCGTCTTGTTCACGT
AAGGCGCCAGGGCCACGACGCTCGAGACCCCCGCGATGGGCAGGTAGCGCGTGAGGCCGGGCGCCGGGTC
GCGGGCCCCGGGCTCGGGGCCGCCCTCCGCGTGGCGCGTCTTCCTGGCACACTTCCTCGGCCCCCGCGGC
GCAGCAGCGCGGGGGCCGAGGGAGGTTTCTCGTCTCTCCCCAGCGCCGGACGCGGACGCGACGCTCCCAC
CAGCCCCGCCCGCAGAGGAAGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGC
GGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGCGGCGACC
GCGGCCTGGGACGACGGAGACGCCGACGGGGGCGCGGCGCCCGCGGACGCCGGGGCGAGCGGCCCGTGGC
CGCGGTCGCCCGAGTCCGAGTCCGGGGCCCGGCGCGGCGCCGCCCTCTTGGCCCCCACCCCCTGGGGGGC
GAGGGGCGAGCGCGGGGCGGCGGAGGAAGAGGCGGAGGACGAGGCCGCGGGGCCCGAGTCCGACCCGCGC
CTCTTCCGGGGGCGGGCCGCCGCCCCCTCCGCGGCGTGGGGGGCGGCACCGGGGGTGTTGGTGCCGCGGG
GGACCCCGGGTCCTCCCTCCGCGCCCGGCCCTCCCGACCCGCGCGCGTCGGTCGCGCCTGCCCGGCCCAG
ACTCTGTGCTTGGGTGTCGGTCTGAGCCTGGGTCATGCGCGACCGGGGCGCGCGGTGCGCGTCCACCGGC
ACGGCGGGCGGCGCGGGCCCGGCCGCGTCCGCGCTCGCAGACACCACGGGGGCGGCGGCGGCGCGGGGCG
GACTCCGGACGCGCGGGGCGACGGCCGCGCGGGGGCGCGCGGCGCGCCCCGACGACTGTGGCAGACCTCC
CCCCCCGGGGCCCGAGGACACCTGTGCGGAGGAGGAGGAGACAAAGGAGAGCGGCCCGGGGCCCGCGGGG
CGGCGCGGAGACGGCGGGGGAGAGTCGCTGATGACTATGGGGGGCTCCTGGGCCGCGCGGGGCTGTCTCG
CGGGGGGCGTCCTGCCCTCCGCCGCCGCGGCGTCTTCGCCCACCCGCCGCGCCTGCGCGCGCCCCCCGCC
GGCCGCAGGGGGAAGAGAGGCCACTCTCGGCACGACGGCCGCGACGGCAGGGCCGCCCCCAGACCCAGAT
CCCACCCCCGCCCGCAACGGGGCGCCGCCGCTGCTGCTGCTCCGCGGGGCGCCAGGGGGCGCCGGTCGGG
TCGCGGCGGGCTGGGAGGTTCCGCGGGTCGCCCCCGCACCGCCGCCCCCGCGCCGGGGCGCTCTTCGGGG
GGCGGGCGGGACGTAGTCCACTGCAGAGGGAGACAGAGACGGGAGCCCCCGGTTAGTGCCCGACCCCCGC
CCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGA
CCCCCGCCCGACCCCCGCCCGACCCCCGCCCGCCCCCCGCCCGACCCCCGCCCGCCCTCACCGTCGGCCA
GGTCATCGTCCTCGTCGTCCGTGCCGGGCCACGGGGGGGTGGGCGACAGGGCGCGGACCGTGTGTCCCCC
CAGCGACAGGGAGCGCGGGGCCGTCCGCGGGTTGCCCGTCCAGATAAAGTCCACGGCCGTGCCGGCCCGC
ACGGCCGCCTCGGCCTCCACGCGGGTCCGGGGGTCGTTCACTATCGGGATGGTGCTGAACGACCCGCTGG
CGGTCACGCCCACTATCAGGTACGCCACCGGGGTGTTGCACAGGGGACACGTGTTGCGCAACGGAATCCA
GGTCTTCATGCACGGGATGCAGAAGGGGTGCAGGCAGGGAAAACTCTGGCAGCGCAGGGGCGGGGCGATC
TCGTCCGTGCACACGGCACACACGTCGCCCCCCCCTCCCGCTTCCGCTTCCTCCTCACCCACGGGCCCAC
CCCCACAGGATCCCTGCGCGTCGGCGGGCGTGGGGCTGCCCTGGCGCTCGGCCGGGGGCCGGGCCGGGGG
CGTGGCCGCGTCCATCAGGCCCGCCTCGAACATCTCCGTGTCCGTGCTGCCCGCCTCGGAGGTGGAGTCG
CGGTGAAGGTCGTCGTCAGAGATTCCCACCTCGGTCTCCTCCTCCGAGTCGCTGCTGGCGAGCCACTGCA
TGTCGTTGAGCATCCCCCAGGCGTGCGGGGCGGCGGGCTGCTTGACAAAGCAACGGGGGGGATTTAGAGG
GCGCGGGGCGTGAGGCGGGACCCCCGCGCCGTGTCCCCCGTGTCCCTCCCTCACCCCGGCCCCCCGCCCG
CTGCTTTTTGTTCGGAAGGGGGGGAGAAAGGGGTCCGTAACCAAAGGTGGTCTGCGTCCTTTGGATTCCG
ACCCCTCGTCTCCCCCCCTGTCCCCCGCTCTCGGGCTCCTCCCTGCCTCCCTCGCCCCCCCAGAGGGTCG
GGGGGCGGCGCACGGCCCACGGGGGTCCCCCGACCGCTTAAGCGGGCCGGGGGTCGGCCCCGTCAAGCGT
CCCCGCCCCCGAGCCCACCGCCCGCGACCACCCCCAACCCGCAGCCGGGTGGTCCGGGGAAAAGGGGGGG
CCTGAGACCCGGGGGTCGCCCTCTCACCGTGCCGGGGGTCTGCCGCGGCGGCCGCTCGGGGCCGGGGTCC
GCCCGGGAGCTCGTGCCGGGCCGGGGTTCCA

Protein Sequence : Show Sequence

>gi|109676722|ref|NP_044528.2| ubiquitin E3 ligase ICP0 [Human herpesvirus 2]
MEPRPGTSSRADPGPERPPRQTPGTPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGST
DTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQS
FPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFI
WTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAA
TRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPP
ARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRS
PPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGV
PRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDR
GHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGA
GGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAP
YVNKTVTGDCLPVLDMETGHIGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPAS
EWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE

Molecule Role : Virmugen
Molecule Role Annotation : A live-attenuated HSV-2 ICP0 virus provides significant protection against wild-type HSV-2 (MS strain) challenge in mice (Halford et al., 2011).
Related Vaccine(s): Herpes simplex virus 2 ICP0 mutant vaccine

6. ICP27

Gene Name : ICP27
Sequence Strain (Species/Organism) : Herpes simplex virus type 1
VO ID : VO_0011101
NCBI Protein GI : 75812153
Other Database IDs : CDD:293457
CDD:283185
Taxonomy ID : 10298
Gene Strand (Orientation) : ?
Protein Name : ICP27
Protein pI : 6.82
Protein Weight : 53658
Protein Length : 566
Protein Note : Identical sequence is also seen in starin: BBY-C-1802;
laboratory host: Vero cell, human embryonic lung cell

Protein Sequence : Show Sequence

>BAE44982.1 ICP27 [Human alphaherpesvirus 1]
MATDIDMLIDLGLDLSDSDLDEDPPEPAESRRDDLASDSSGECSSSDEDMEDPHGEDGPEPILDAARPAV
RPSRPEDPGVPSTQTPRPTERQGPNDPQPAPHSVWSRLGARRPSCSPEQHGGKVARLQPPPTKAQPARGG
RRGRRRGRGRGGPGAADGLSDPRRRAPRTNRNPGGPRPGAGWTDGPGAPHGEAWRGSEQPDPPGGPRTRG
VRQAPPPLMTLAIAPPPADPRAPAPERKAPAADTIDATTRLVLRSISERAAVDRISESFGRSAQVMHDPF
GGQPFPAANSPWAPVLADQGGPFDAETRRVSWETLVAHGPSLYRTFAGNPRAASTAKAMRDCVLRQENFI
EALASADETLAWCKMCIHHNLPLRPQDPIIGTAAAVLDNLATRLRPFLQCYLKARGLCGLDELCSRRRLA
DIKDIASFVFVILARLANRVERGVAEIDYATLGVGVGEKMHFYLPGACMAGLIEILDTHRQECSSRVCEL
TASHIVAPPYVHGKYFYCNSLF

Molecule Role : Protective antigen
Molecule Role Annotation : Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge with HSV (Goel et al., 2005).
Related Vaccine(s): Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27

7. ICP27 from Herpes simplex virus type 2

Gene Name : ICP27 from Herpes simplex virus type 2
Sequence Strain (Species/Organism) : Herpes simplex virus type 2
VO ID : VO_0011100
NCBI Protein GI : 124181
Other Database IDs : CDD:293457
CDD:283185
Taxonomy ID : 10315
Gene Strand (Orientation) : ?
Protein Name : mRNA export factor
Protein pI : 7.52
Protein Weight : 56538.03
Protein Length : 697
Protein Note : Immediate-early protein IE63; Infected cell protein 27; VMW63; ICP27

Protein Sequence : Show Sequence

>sp|P28276.1|ICP27_HHV2H RecName: Full=mRNA export factor; AltName: Full=Immediate-early protein IE63; AltName: Full=Infected cell protein 27; Short=ICP27; AltName: Full=VMW63
MATDIDMLIDLGLDLSDSELEEDALERDEEGRRDDPESDSSGECSSSDEDMEDPCGDGGAEAIDAAIPKG
PPARPEDAGTPEASTPRPAARRGADDPPPATTGVWSRLGTRRSASPREPHGGKVARIQPPSTKAPHPRGG
RRGRRRGRGRYGPGGADSTPKPRRRVSRNAHNQGGRHPASARTDGPGATHGEARRGGEQLDVSGGPRPRG
TRQAPPPLMALSLTPPHADGRAPVPERKAPSADTIDPAVRAVLRSISERAAVERISESFGRSALVMQDPF
GGMPFPAANSPWAPVLATQAGGFDAETRRVSWETLVAHGPSLYRTFAANPRAASTAKAMRDCVLRQENLI
EALASADETLAWCKMCIHHNLPLRPQDPIIGTAAAVLENLATRLRPFLQCYLKARGLCGLDDLCSRRRLS
DIKDIASFVLVILARLANRVERGVSEIDYTTVGVGAGETMHFYIPGACMAGLIEILDTHRQECSSRVCEL
TASHTIAPLYVHGKYFYCNSLF

Molecule Role : Protective antigen
Molecule Role Annotation : Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality (Haynes et al., 2006).
Related Vaccine(s): Herpes simplex virus type 2 DNA vaccine encoding ICP27

8. TK

Gene Name : TK
Sequence Strain (Species/Organism) : Human herpesvirus 1
NCBI Gene ID : 2703374
NCBI Protein GI : 9629403
Locus Tag : HHV1gp034
Genbank Accession : X14112
Protein Accession : NP_044624
3D structure: PDB ID : 1KIM
Taxonomy ID : 10298
Gene Starting Position : 46607
Gene Ending Position : 47910
Gene Strand (Orientation) : -
Protein Name : thymidine kinase
Protein pI : 8.59
Protein Weight : 38836.64
Protein Length : 376
Protein Note : 2.7.1.21

DNA Sequence : Show Sequence

>gi|9629378:46607-47910 Human herpesvirus 1, complete genome
TTTTATTCTGTCTTTTTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCTCCTTCCGTGTTTCAGT
TAGCCTCCCCCATCTCCCGGGCAAACGTGCGCGCCAGGTCGCAGATCGTCGGTATGGAGCCTGGGGTGGT
GACGTGGGTCTGGACCATCCCGGAGGTAAGTTGCAGCAGGGCGTCCCGGCAGCCGGCGGGCGATTGGTCG
TAATCCAGGATAAAGACATGCATGGGACGGAGGCGTTTGGCCAAGACGTCCAAAGCCCAGGCAAACACGT
TATACAGGTCGCCGTTGGGGGCCAGCAACTCGGGGGCCCGAAACAGGGTAAATAACGTGTCCCCGATATG
GGGTCGTGGGCCCGCGTTGCTCTGGGGCTCGGCACCCTGGGGCGGCACGGCCGCCCCCGAAAGCTGTCCC
CAATCCTCCCGCCACGACCCGCCGCCCTGCAGATACCGCACCGTATTGGCAAGCAGCCCATAAACGCGGC
GAATCGCGGCCAGCATAGCCAGGTCAAGCCGCTCGCCGGGGCGCTGGCGTTTGGCCAGGCGGTCGATGTG
TCTGTCCTCCGGAAGGGCCCCCAACACGATGTTTGTGCCGGGCAAGGTCGGCGGGATGAGGGCCACGAAC
GCCAGCACGGCCTGGGGGGTCATGCTGCCCATAAGGTATCGCGCGGCCGGGTAGCACAGGAGGGCGGCGA
TGGGATGGCGGTCGAAGATGAGGGTGAGGGCCGGGGGCGGGGCATGTGAGCTCCCAGCCTCCCCCCCGAT
ATGAGGAGCCAGAACGGCGTCGGTCACGGCATAAGGCATGCCCATTGTTATCTGGGCGCTTGTCATTACC
ACCGCCGCGTCCCCGGCCGATATCTCACCCTGGTCGAGGCGGTGTTGTGTGGTGTAGATGTTCGCGATTG
TCTCGGAAGCCCCCAACACCCGCCAGTAAGTCATCGGCTCGGGTACGTAGACGATATCGTCGCGCGAACC
CAGGGCCACCAGCAGTTGCGTGGTGGTGGTTTTCCCCATCCCGTGGGGACCGTCTATATAAACCCGCAGT
AGCGTGGGCATTTTCTGCTCCAGGCGGACTTCCGTGGCTTTTTGTTGCCGGCGAGGGCGCAACGCCGTAC
GTCGGTTGTTATGGCCGCGAGAACGCGCAGCCTGGTCGAACGCAGACGCGTGTTGATGGCAGGGGTACGA
AGCCATACGCGCTTCTACAAGGCGCTGGCCGAAGAGGTGCGGGAGTTTCACGCCACCAAGATCTGCGGCA
CGCTGTTGACGCTGTTAAGCGGGTCGCTGCAGGGTCGCTCGGTA

Protein Sequence : Show Sequence

>gi|9629403|ref|NP_044624.1| thymidine kinase [Human herpesvirus 1]
MASYPCHQHASAFDQAARSRGHNNRRTALRPRRQQKATEVRLEQKMPTLLRVYIDGPHGMGKTTTTQLLV
ALGSRDDIVYVPEPMTYWRVLGASETIANIYTTQHRLDQGEISAGDAAVVMTSAQITMGMPYAVTDAVLA
PHIGGEAGSSHAPPPALTLIFDRHPIAALLCYPAARYLMGSMTPQAVLAFVALIPPTLPGTNIVLGALPE
DRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGGSWREDWGQLSGAAVPPQGAEPQSNAGP
RPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQT
HVTTPGSIPTICDLARTFAREMGEAN

Molecule Role : Virmugen
Molecule Role Annotation : A thymidine kinase-deficient (TK) mutant was found to be attenuated in mice. This mutant induced complete protection from challenge with wild type HSV (Field and Wildy, 1978).
Related Vaccine(s): Herpes simplex virus 1 TK mutant vaccine

9. UL27

Gene Name : UL27
Sequence Strain (Species/Organism) : Herpes simplex virus type 2
VO ID : VO_0011097
NCBI Protein GI : 1869850
Other Database IDs : CDD:223014
GOA:P08666
InterPro: IPR000234
UniProtKB/UniProt: P08666
Taxonomy ID : 10310
Gene Strand (Orientation) : ?
Protein Name : glycoprotein B
Protein pI : 8.42
Protein Weight : 93087.81
Protein Length : 972
Protein Note : glycoprotein BALF4; Provisional

Protein Sequence : Show Sequence

>CAB06752.1 glycoprotein B [Human alphaherpesvirus 2]
MRGGGLICALVVGALVAAVASAAPAAPAAPRASGGVAATVAANGGPASRPPPVPSPATTKARKRKTKKPP
KRPEATPPPDANATVAAGHATLRAHLREIKVENADAQFYVCPPPTGATVVQFEQPRRCPTRPEGQNYTEG
IAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINTKGVCRSTAKYVR
NNMETTAFHRDDHETDMELKPAKVATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARSVYPYD
EFVLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATSPTTRNLLTTPKFTVAWD
WVPKRPAVCTMTKWQEVDEMLRAEYGGSFRFSSDAISTTFTTNLTEYSLSRVDLGDCIGRDAREAIDRMF
ARKYNATHIKVGQPQYYLATGGFLIAYQPLLSNTLAELYVREYMREQDRKPRNATPAPLREAPSANASVE
RIKTTSSIEFARLQFTYNHIQRHVNDMLGRIAVAWCELQNHELTLWNEARKLNPNAIASATVGRRVSARM
LGDVMAVSTCVPVAPDNVIVQNSMRVSSRPGTCYSRPLVSFRYEDQGPLIEGQLGENNELRLTRDALEPC
TVGHRRYFIFGGGYVYFEEYAYSHQLSRADVTTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLLDYT
EVQRRNQLHDLRFADIDTVIRADANAAMFAGLCAFFEGMGDLGRAVGKVVMGVVGGVVSAVSGVSSFMSN
PFGALAVGLLVLAGLVAAFFAFRYVLQLQRNPMKALYPLTTKELKTSDPGGVGGEGEEGAEGGGFDEAKL
AEAREMIRYMALVSAMERTEHKARKKGTSALLSSKVTNMVLRKRNKARYSPLHNEDEAGDEDEL

Molecule Role : Protective antigen
Molecule Role Annotation : The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection (Kim et al., 2009).
Related Vaccine(s): Herpes simplex virus DNA vaccine ∆gB-2 encoding gB , Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis , Herpes simplex virus type 2 DNA vaccine encoding GB

10. UL27 from Herpes simplex virus type 1

Gene Name : UL27 from Herpes simplex virus type 1
Sequence Strain (Species/Organism) : Human herpesvirus 1
VO ID : VO_0011099
NCBI Gene ID : 2703455
NCBI Protein GI : 9629408
Locus Tag : HHV1gp041
Genbank Accession : X14112
Protein Accession : NP_044629
3D structure: PDB ID : 2GUM
Taxonomy ID : 10298
Gene Starting Position : 53057
Gene Ending Position : 56079
Gene Strand (Orientation) : -
Protein Name : envelope glycoprotein B
Protein pI : 8.23
Protein Weight : 93545.07
Protein Length : 904
Protein Note : glycoprotein BALF4; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA; BALF4 is a transmembrane glycoprotein found in the lipid envelope of several herpesviruses

DNA Sequence : Show Sequence

>NC_001806.1:53057-56079 Human herpesvirus 1, complete genome
TTTTATTTACAACAAACCCCCCATCACAGGTCGTCCTCGTCGGCGTCACCGTCTTTGTTGGGAACTTGGG
TGTAGTTGGTGTTGCGGCGCTTGCGCATGACCATGTCGGTGACCTTGGCGCTGAGCAGCGCGCTCGTGCC
CTTCTTCTTGGCCTTGTGTTCCGTGCGCTCCATGGCAGACACCAGGGCCATGTACCGTATCATCTCCCGG
GCCTCGGCTAGCTTGGCCTCGTCAAAGTCGCCGCCCTCCTCGCCCTCCCCGGACGCGTCCGGGTTGGTGG
GGTTCTTGAGCTCCTTGGTGGTTAGCGGGTACAGGGCCTTCATGGGGTTGCTCTGCAGCCGCATGACGTA
GCGAAAGGCGAAGAAGGCCGCCGCCAGGCCGGCCAGGACCAACAGACCCACGGCCAGCGCCCCAAAGGGG
TTGGACATGAAGGAGGACACGCCCGACACGGCCGATACCACGCCGCCCACGATGCCCATCACCACCTTGC
CGACCGCGCGCCCCAGGTCGCCCATCCCCTCGAAGAACGCGCCCAGGCCCGCAAACATGGCGGCGTTGGC
GTCGGCGTGGATGACCGTGTCGATGTCGGCGAAGCGCAGGTCGTGCAGCTGGTTGCGGCGCTGGACCTCC
GTGTAGTCCAGCAGGCCGCTGTCCTTGATCTCGTGGCGGGTGTACACCTCCAGGGGGACAAACTCGTGAT
CCTCCAGCATGGTGATGTTGAGGTCGATGAAGGTGCTGACGGTGGTGATGTCGGCGCGGCTCAGCTGGTG
GGAGTACGCGTACTCCTCGAAGTACACGTAGCCCCCACCGAAGGTGAAGTAGCGCCGGTGTCCCACGGTG
CACGGCTCGATCGCATCGCGCGTCAGCCGCAGCTCGTTGTTCTCCCCCAGCTGCCCCTCGACCAACGGGC
CCTGGTCTTCGTACCGAAAGCTGACCAGGGGGCGGCTGTAGCAGGCCCCGGGCCGCGAGCTGATGCGCAT
CGAGTTTTGGACGATCACGTTGTCCGCGGCGACCGGCACGCACGTGGAGACGGCCATCACGTCGCCGAGC
ATCCGCGCGCTCACCCGCCGGCCCACGGTGGCCGAGGCGATGGCGTTGGGGTTCAGCTTGCGGGCCTCGT
TCCACAGGGTCAGCTCGTGATTCTGCAGCTCGCACCACGCGATGGCAACGCGGCCCAACATATCGTTGAC
ATGGCGCTGTATGTGGTTGTACGTAAACTGCAGCCTGGCGAACTCGATGGAGGAGGTGGTCTTGATGCGC
TCCACGGACGCGTTGGCGCTGGCCCCGGGCGGCGGGGGCGTGGGGTTTGGGGGCTTGCGGCTCTGCTCGC
GGAGGTGTTCCCGCACGTACAGCTCCGCGAGCGTGTTGCTGAGAAGGGGCTGGTACGCGATCAGAAAGCC
CCCATTGGCCAGGTAGTACTGCGGCTGGCCCACCTTGATGTGCGTCGCGTTGTACCTGCGGGCGAAGATG
CGGTCCATGGCGTCGCGGGCGTCCTTGCCGATGCAGTCCCCCAGGTCCACGCGCGAGAGCGGGTACTCGG
TCAGGTTGGTGGTGAAGGTGGTGGATATGGCGTCGGAAGAGAATCGGAAGGAGCCGCCGTACTCGGAGCG
CAGCATCTCGTCCACCTCCTGCCACTTGGTCATGGTGCAGACCGACGGGCGCTTTGGCACCCAGTCCCAG
GCCACGGTGAACTTGGGGGTCGTGAGCAGGTTCCGGGTGGTCGGCGCCGTGGCCCGGGCCTTGGTGGTGA
GGTCGCGCGCGTAGAAGCCGTCGACCTGCTTGAAGCGGTCGGCGGCGTAGCTGGTGTGTTCGGTGTGCGA
CCCCTCCCGGTAGCCGTAAAACGGGGACATGTACACAAAGTCGCCAGTCGCCAACACAAACTCGTCGTAC
GGGTACACCGAGCGCGCGTCCACCTCCTCGACGATGCAGTTTACCGTCGTCCCGTACCGGTGGAACGCCT
CCACCCGCGAGGGGTTGTACTTGAGGTCGGTGGTGTGCCAGCCCCGGCTCGTGCGGGTCGCGGCGTTGGC
CGGTTTCAGCTCCATGTCGGTCTCGTGGTCGTCCCGGTGAAACGCGGTGGTCTCCAGGTTGTTGCGCACG
TACTTGGCCGTGGACCGACAGACCCCCTTGGCGTTGATCTTGTCGATCACCTCCTCGAAGGGGACGGGGG
CGCGGTCCTCAAAGATCCCCATAAACTGGGAGTAGCGGTGGCCGAACCACACCTGCGAAACGGTGACGTC
TTTGTAGTACATGGTGGCCTTGAACTTGTACGGGGCGATGTTCTCCTTGAAGACCACCGCGATGCCCTCC
GTGTAGTTCTGACCCTCGGGCCGGGTCGGGCAGCGGCGCGGCTGCTCGAACTGCACCACCGTGGCGCCCG
TGGGGGGTGGGCACACGTAAAAGTTTGCATCGGTGTTCTCCGCCTTGATGTCCCGCAGGTGCTCGCGCAG
GGTGGCGTGGCCCGCGGCGACGGTCGCGTTGTCGCCGGCGGGGCGCGGCGGCTTTGGGGGTTTCGGTTTT
CTGTTCTTCTTCGGTTTCGGGTCCCCCGTTGGGGGGGCGCCAGGGGCGGGCGGCGCCGGAGTGGCAGGGC
CCCCGTTCGCCGCCTGGGTCGCGGCCGCGACCCCAGGCGTGCCGGGGGAACTCGGAGCCGCCGACGCCAC
CAGGACCCCCAGCGTCAACCCCAAGAGCGCCCATACGACGAACCACCGGCGCCCCCGCGCGGGGGCGCCC
TGGCGCATGGCGGGACTACGGGGGCCCGTCGTGCCCCCCGTCAGGTAGCCTGGGGGCGAGGTGCTGGAGG
ACCGAGTAGAGGATCGAGAAAACGTCTCGGTCGTAGACCACGACCGACCGGGGGCCGATACAGCCGTCGG
GGGCGCTCTCGACGATGGCCACCAGCGGACAGTCGGAGTCGTACGTGAGATATACGCCGGGCGGGTAACG
GTAACGACCTTCGGAGGTCGGGCGGCTGCAGTCCGGGCGGCGCAACTCGAGCTCCCCGCACCGGTAGACC
GAGGCAAAGAGTG

Protein Sequence : Show Sequence

>NP_044629.1 envelope glycoprotein B [Human herpesvirus 1]
MRQGAPARGRRWFVVWALLGLTLGVLVASAAPSSPGTPGVAAATQAANGGPATPAPPAPGAPPTGDPKPK
KNRKPKPPKPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPPTGATVVQFEQPRRCPTRPEGQ
NYTEGIAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRST
AKYVRNNLETTAFHRDDHETDMELKPANAATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARS
VYPYDEFVLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATAPTTRNLLTTPKF
TVAWDWVPKRPSVCTMTKWQEVDEMLRSEYGGSFRFSSDAISTTFTTNLTEYPLSRVDLGDCIGKDARDA
MDRIFARRYNATHIKVGQPQYYLANGGFLIAYQPLLSNTLAELYVREHLREQSRKPPNPTPPPPGASANA
SVERIKTTSSIEFARLQFTYNHIQRHVNDMLGRVAIAWCELQNHELTLWNEARKLNPNAIASATVGRRVS
ARMLGDVMAVSTCVPVAADNVIVQNSMRISSRPGACYSRPLVSFRYEDQGPLVEGQLGENNELRLTRDAI
EPCTVGHRRYFTFGGGYVYFEEYAYSHQLSRADITTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLL
DYTEVQRRNQLHDLRFADIDTVIHADANAAMFAGLGAFFEGMGDLGRAVGKVVMGIVGGVVSAVSGVSSF
MSNPFGALAVGLLVLAGLAAAFFAFRYVMRLQSNPMKALYPLTTKELKNPTNPDASGEGEEGGDFDEAKL
AEAREMIRYMALVSAMERTEHKAKKKGTSALLSAKVTDMVMRKRRNTNYTQVPNKDGDADEDDL

Molecule Role : Protective antigen
Molecule Role Annotation : Study demonstrated that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB, UL27)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection in mice (Orr et al., 2007).
Related Vaccine(s): Herpes simplex virus DNA vaccine gB-DNA encoding gB , Herpes simplex virus DNA vaccine gBDNA encoding gB , Herpes simplex virus DNA vaccine pSIN-gB encoding gB , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP

11. UL29

Gene Name : UL29
Sequence Strain (Species/Organism) : Human herpesvirus 1
NCBI Gene ID : 2703458
NCBI Protein GI : 9629410
Locus Tag : HHV1gp41.5
Genbank Accession : X14112
Protein Accession : NP_044631
Taxonomy ID : 10298
Gene Starting Position : 58408
Gene Ending Position : 62052
Gene Strand (Orientation) : -
Protein Name : single-stranded DNA-binding protein
Protein pI : 6.48
Protein Weight : 119914.97
Protein Length : 1196

DNA Sequence : Show Sequence

>gi|9629378:58408-62052 Human herpesvirus 1, complete genome
ATTTATTTTACACACATTCCCCGCCCCGCCCTAGGTTCCCCCACCCCCCAACCCCTCACAGCATATCCAA
CGTCAGGTCTCCCTTTTTGTCGGGGGGCCCCTCCCCAAACGGGTCATCCCCGTGGAACGCCCGTTTGCGG
CCGGCAAATGCCGGTCCCGGGGCCCCCGGGCCGCCGAACGGCGTCGCGTTGTCGTCCTCGCAGCCAAAAT
CCCCAAAGTTAAACACCTCCCCGGCGTTGCCGAGTTGGCTGACTAGGGCCTCGGCCTCGTGCGCCACCTC
CAGGGCCGCGTCCGTCGACCACTCGCCGTTGCCGCGCTCCAGGGCACGCGCGGTCAGCTCCATCATCTCC
TCGCTTAGGTACTCGTCCTCCAGGAGCGCCAGCCAGTCCTCGATCTGCAGCTGCTGGGTGCGGGGCCCCA
GGCTTTTCACGGTCGCCACGAACACGCTACTGGCGACGGCCGCCCCGCCCTCGGAGATAATGCCCCGGAG
CTGCTCGCACAGCGAGCTTTCGTGCGCTCCGCCGCCGAGGCTTGAGGCCGCGCACACAAACCCGGCCCGG
GGACAGGCCAGGACGAACTTGCGGGTGCGGTCAAAAATAAGGAGCGGGCACGCGTTTTTGCCGCCCATCA
GGCTGGCCCAGTTCCCGGCCTGAAACACACGGTCGTTGCCGGCCATGCCGTAGTACTTGCTGATGCTCAA
CCCCAACACGACCATGGGGCGCGCCGCCATGACGGGCCGCAGCAGGTTGCAGCTGGCGAACATGGACGTC
CACGCGCCCGGATGCGCGTCCACGGCGTCCATCAGCGCGCGGGCCCCGGCCTCCAGGCCCGCCCCGCCCT
GCGCGGACCACGCGGCCGCAGCCTGCACGCTGGGGGGACGGCGGGACCCCGCGATGATGGCCGTAAGGGT
GTTGATGAAGTATGTCGAGTGATCGCAGTACCGCAGAATCTGGTTTGCCATGTAGTACATCGCCAGCTCG
CTCACGTTGTTGGGGGCCAGGTTAATAAAGTTTATCGCGCCGTAGTCCAGGGAAAACTTTTTAATGAACG
CGATGGTCTCGATGTCCTCGCGCGACAGGAGCCGGGCGGGAAGCTGGTTGCGTTGGAGGGCCGTCCAGAA
CCACTGCGGGTTCGGCTGGTTGGACCCCGGGGGCTTGCCGTTGGGGAAGATGGCCGCGTGGAACTGCTTC
AGCAGAAAGCCCAGCGGTCCGAGGAGGATGTCCACGCGCTTGTCGGGCTTCTGGTAGGCGCTCTGGAGGC
TGGCGACCCGCGCCTTGGCGGCCTCGGACGCGTTGGCGCTCGCGCCCGCGAACAACACGCGGCTCTTGAC
GCGCAGCTCCTTGGGAAACCCCAGGGTCACGCGGGCAACGTCGCCCTCGAAGCTGCTCTCGGCGGGGGCC
GTCTGGCCGGCCGTTAGGCTGGGGGCGCAGATAGCCGCCCCCTCCGAGAGCGCGACCGTCAGCGTTTTGG
CCGACAGAAACCCGTTGTTAAACATGTCCATCACGCGCCGCCGCAGCACCGGTTGGAATTGATTGCGAAA
GTTGCGCCCCTCGACCGACTGCCCGGCGAACACCCCGTGGCACTGACTCAGGGCCAGGTCCTGGTACACG
GCGAGGTTGGATCGCCGCCCGAGAAGCTGAAGCAGGGGGCACGGCCCGCACGCGTACGGGTCCAGCGTCA
GGGACATGGCGTGGTTGGCCTCGCCCAGACCGTCGCGAAACTTGAAGTTCCTCCCCTCCACCAGGTTGCG
CATCAGCTGCTCCACCTCGCGGTCCACGACCTGCCTGACGTTGTTCACCACCGTATGCAGGGCCTCGCGG
TTGGTGATGATGGTCTCCAGCCGCCCCATGGCCGTGGGGACCGCCTGGTCCACGTACTGCAGGGTCTCGA
GTTCGGCCATGACGCGCTCGGTCGCCGCGCGGTACGTCTCCTGCATGATGGTCCGGGCGGTCTCGGATCC
GTCCGCGCGCTTCAGGGCCGAGAAGGCGGCGTAGTTTCCCAGCACGTCGCAGTCGCTGTACATGCTGTTC
ATGGTCCCGAAGACGCCGATGGCTCCGCGGGCGGCGCTGGCGAACTTTGGATGGCGCGCCCGGAGGCGCA
TGAGCGTCGTGTGTACGCAGGCGTGGCGCGTGTCGAAGGTGCATAGGTTACAGGGCACGTCGGTCTGGTT
GGAGTCCGCGACGTATCGAAACACGTCCATCTCCTGGCGCCCGACGATCACGGCGCCGTCGCAGCGCTCC
AGGTAAAACAGCATCTTGGCCAGCAGCGCCGGGGAAAACCCACACAGCATGGCCAGGTGCTCGCCGGCAA
ATTCCTGGGTTCCGCCGACGAGGGGCGCGGTGGGCCGACCCTCGAACCCGGGCACCACGTGTCCCTCGCG
GTCCACCTGTGGGTTGGCCGCCACGTGGGTCCCGGGCACGAGGAAGAAGCGGTAAAAGGAGGGTTTGCTG
TGGTCCTTTGGGTCCGCCGGGCCGGCGTCGTCCACCTCGGTGAGATGGAGGGCCGAGTTGGTGCTAAATA
CCATGGCCCCCACGAGTCCCGCGGCGCGCGCCAGGTACGCCCCGACGGCGTTGGCGCGGGCCGCGGCCGT
GTCCTGGCCCTCGAACAGCGGCCACGCGGAGATGTCGGTGGGCGGCTCGTCAAAGACGGCCATCGACACG
ATAGACTCGAGGGCCAGGGCGGCGTCTCCGGCCATGACGGAGGCCAGGCGCTGTTCGAACCCGCCCGCCG
CGCCCTTGCCGCCGCCGTCGCGCCCGCCCCGCGGGGTCTTACCCTGGCTGGCTTCGAAGGCCGTGAACGT
AATGTCGGCGGGGAGGGCGGCGCCCTCGTGGTTTTCGTCAAACGCCAGGTGGGCGGCCGCGCGGGCCACG
GCGTCCACGTTTCGGCATCGCAGTGCCACGGCGGCGGGTCCCACGACCGCCTCGAACAGGAGGCGGTTGA
GGGGGCGGTTAAAAAACGGAAGCGGGTAGGTAAATTTCTCCCCGATCGATCGGTGGTTGGCGTTGAACGG
CTCTGCGATGACACGGCTAAAATCCGGCATGAACAGCTGCAACGGGTACACGGGTATGCGGTGCACCTCC
GCCCCGCCTATGGTTACCTTGTCCGAGCCTCCCAGGTGCAGAAAGGTGTTGTTGATGCACACGGCCTCCT
TGAAGCCCTCGGTAACGACCAGATACAGGAGGGCGCGGTCCGGGTCCAGGCCGAGGCGCTCACACAGCGC
CTCCCCCGTCGTCTCGTGTTTGAGGTCGCCGGGCCGGGGGGTGTAGTCCGAAAAGCCAAAATGGCGGCGT
GCCCGCTCGCAAAGTCGCGTCAGGTTCGGGGCCTGGGTGCTGGGGTCCAGGTGCCGGCCGCCGTGAAAGA
CGTACACGGACGAGCTGTAGTGCGAGGGCGTCAGTTTCAGGGACACCGCGGTACCCCCGAGCCCCGTCGT
GCGAGAACCCACGACCACGGCCACGTTGGCCTCAAAGCCGCTCTCCACGGTCAGGCCCACGACCAGGGGC
GCCACGGCGACGTCGGAATCGCCGCTGCGTGCCGACAGTAACGCCAGAAGCTCGATGCCTTCGGACGGAC
ACGCGCGAGCGTACACGTATCCCAGGGGCCCGGGGGGGACCTTGATGGTGGTTGCCGTCTTGGGCTTTGT
CTCCA

Protein Sequence : Show Sequence

>gi|9629410|ref|NP_044631.1| single-stranded DNA-binding protein [Human herpesvirus 1]
METKPKTATTIKVPPGPLGYVYARACPSEGIELLALLSARSGDSDVAVAPLVVGLTVESGFEANVAVVVG
SRTTGLGGTAVSLKLTPSHYSSSVYVFHGGRHLDPSTQAPNLTRLCERARRHFGFSDYTPRPGDLKHETT
GEALCERLGLDPDRALLYLVVTEGFKEAVCINNTFLHLGGSDKVTIGGAEVHRIPVYPLQLFMPDFSRVI
AEPFNANHRSIGEKFTYPLPFFNRPLNRLLFEAVVGPAAVALRCRNVDAVARAAAHLAFDENHEGAALPA
DITFTAFEASQGKTPRGGRDGGGKGAAGGFEQRLASVMAGDAALALESIVSMAVFDEPPTDISAWPLFEG
QDTAAARANAVGAYLARAAGLVGAMVFSTNSALHLTEVDDAGPADPKDHSKPSFYRFFLVPGTHVAANPQ
VDREGHVVPGFEGRPTAPLVGGTQEFAGEHLAMLCGFSPALLAKMLFYLERCDGAVIVGRQEMDVFRYVA
DSNQTDVPCNLCTFDTRHACVHTTLMRLRARHPKFASAARGAIGVFGTMNSMYSDCDVLGNYAAFSALKR
ADGSETARTIMQETYRAATERVMAELETLQYVDQAVPTAMGRLETIITNREALHTVVNNVRQVVDREVEQ
LMRNLVEGRNFKFRDGLGEANHAMSLTLDPYACGPCPLLQLLGRRSNLAVYQDLALSQCHGVFAGQSVEG
RNFRNQFQPVLRRRVMDMFNNGFLSAKTLTVALSEGAAICAPSLTAGQTAPAESSFEGDVARVTLGFPKE
LRVKSRVLFAGASANASEAAKARVASLQSAYQKPDKRVDILLGPLGFLLKQFHAAIFPNGKPPGSNQPNP
QWFWTALQRNQLPARLLSREDIETIAFIKKFSLDYGAINFINLAPNNVSELAMYYMANQILRYCDHSTYF
INTLTAIIAGSRRPPSVQAAAAWSAQGGAGLEAGARALMDAVDAHPGAWTSMFASCNLLRPVMAARPMVV
LGLSISKYYGMAGNDRVFQAGNWASLMGGKNACPLLIFDRTRKFVLACPRAGFVCAASSLGGGAHESSLC
EQLRGIISEGGAAVASSVFVATVKSLGPRTQQLQIEDWLALLEDEYLSEEMMELTARALERGNGEWSTDA
ALEVAHEAEALVSQLGNAGEVFNFGDFGCEDDNATPFGGPGAPGPAFAGRKRAFHGDDPFGEGPPDKKGD
LTLDML

Molecule Role : Virmugen
Molecule Role Annotation : A UL29 mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 (Morrison and Knipe, 1994).
Related Vaccine(s): Herpes simplex virus 1 UL29 mutant vaccine

12. UL44 from HSV-1

Gene Name : UL44 from HSV-1
Sequence Strain (Species/Organism) : Human alphaherpesvirus 1
VO ID : VO_0011103
NCBI Gene ID : 2703410
NCBI Protein GI : 820945274
Locus Tag : HHV1gp00p31
Genbank Accession : AJ421498
Protein Accession : YP_009137119
Taxonomy ID : 10298
Gene Starting Position : 96311
Gene Ending Position : 98668
Gene Strand (Orientation) : +
Protein Name : envelope glycoprotein C
Protein pI : 7.82
Protein Weight : 50756.04
Protein Length : 511
Protein Note : envelope glycoprotein C; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; the nonessential glycoprotein gC interacts with cell surface proteoglycans, whereas the essential glycoprotein gD is involved in stable secondary attachment

DNA Sequence : Show Sequence

>NC_001806.2:96311-98668 Human herpesvirus 1 strain 17, complete genome
CATGGCCCCGGGGCGGGTGGGCCTTGCCGTGGTCCTGTGGAGCCTGTTGTGGCTCGGGGCGGGGGTGTCC
GGGGGCTCGGAAACTGCCTCCACCGGGCCCACGATCACCGCGGGAGCGGTGACGAACGCGAGCGAGGCCC
CCACATCGGGGTCCCCCGGGTCAGCCGCCAGCCCGGAGGTCACCCCCACATCGACCCCAAACCCCAACAA
TGTCACACAAAACAAAACCACCCCCACCGAGCCGGCCAGCCCCCCAACAACCCCCAAGCCCACCTCCACG
CCCAAAAGCCCCCCCACGTCCACCCCCGACCCCAAACCCAAGAACAACACCACCCCCGCCAAGTCGGGCC
GCCCCACTAAACCCCCCGGGCCCGTGTGGTGCGACCGCCGCGACCCATTGGCCCGGTACGGCTCGCGGGT
GCAGATCCGATGCCGGTTTCGGAATTCCACCCGCATGGAGTTCCGCCTCCAGATATGGCGTTACTCCATG
GGTCCGTCCCCCCCAATCGCTCCGGCTCCCGACCTAGAGGAGGTCCTGACGAACATCACCGCCCCACCCG
GGGGACTCCTGGTGTACGACAGCGCCCCCAACCTAACGGACCCCCACGTGCTCTGGGCGGAGGGGGCCGG
CCCGGGCGCCGACCCTCCGTTGTATTCTGTCACCGGGCCGCTGCCGACCCAGCGGCTGATTATCGGCGAG
GTGACGCCCGCGACCCAGGGAATGTATTACTTGGCCTGGGGCCGGATGGACAGCCCGCACGAGTACGGGA
CGTGGGTGCGCGTCCGCATGTTCCGCCCCCCGTCTCTGACCCTCCAGCCCCACGCGGTGATGGAGGGTCA
GCCGTTCAAGGCGACGTGCACGGCCGCCGCCTACTACCCGCGTAACCCCGTGGAGTTTGTCTGGTTCGAG
GACGACCACCAGGTGTTTAACCCGGGCCAGATCGACACGCAGACGCACGAGCACCCCGACGGGTTCACCA
CAGTCTCTACCGTGACCTCCGAGGCTGTCGGCGGCCAGGTCCCCCCGCGGACCTTCACCTGCCAGATGAC
GTGGCATCGCGACTCCGTGACGTTCTCGCGACGCAATGCCACCGGGCTGGCCCTGGTGCTGCCGCGGCCA
ACCATCACCATGGAATTTGGGGTCCGGCATGTGGTCTGCACGGCCGGCTGCGTCCCCGAGGGCGTGACGT
TTGCCTGGTTCCTGGGGGACGACCCCTCACCGGCGGCTAAGTCGGCCGTTACGGCCCAGGAGTCGTGCGA
CCACCCCGGGCTGGCTACGGTCCGGTCCACCCTGCCCATTTCGTACGACTACAGCGAGTACATCTGTCGG
TTGACCGGATATCCGGCCGGGATTCCCGTTCTAGAACACCACGGCAGTCACCAGCCCCCACCCAGGGACC
CCACCGAGCGGCAGGTGATCGAGGCGATCGAGTGGGTGGGGATTGGAATCGGGGTTCTCGCGGCGGGGGT
CCTGGTCGTAACGGCAATCGTGTACGTCGTCCGCACATCACAGTCGCGGCAGCGTCATCGGCGGTAACGC
AAGACCCCCCCGTTACCTTTTTAATATCTATATAGTTTGGTCCCCCCTCTATCCCGCCCACCGCTGGGCG
CTATAAAGCCGCCACCCTCTCTTCCCTCAGGTCATCCTTGGTCGATCCCGAACGACACACGGCGTGGAGC
AAAACGCCTCCCCCTGAGCCGCTTTCCTACCAACACAACGGCATGCCTCTGCGGGCATCGGAACACGCCT
ACCGGCCCCTGGGCCCCGGGACACCCCCCATGCGGGCTCGGCTCCCCGCCGCGGCCTGGGTTGGCGTCGG
GACCATCATCGGGGGAGTTGTGATCATTGCCGCGTTGGTCCTCGTGCCCTCGCGGGCCTCGTGGGCACTT
TCCCCATGCGACAGCGGATGGCACGAGTTCAACCTCGGGTGCATATCCTGGGATCCGACCCCCATGGAGC
ACGAGCAGGCGGTCGGCGGCTGTAGCGCCCCGGCGACCCTGATCCCCCGCGCGGCTGCCAAACAGCTGGC
CGCCGTCGCACGCGTCCAGTCGGCAAGATCCTCGGGCTACTGGTGGGTGAGCGGAGACGGCATTCGGGCC
TGCCTGCGGCTCGTCGACGGCGTCGGCGGTATTGACCAGTTTTGCGAGGAGCCCGCCCTTCGCATATGCT
ACTATCCCCGCAGTCCCGGGGGCTTTGTTCAGTTTGTAACTTCGACCCGCAACGCGCTGGGGCTGCCGTG
AGGCGCGTGTACTGCGGTCTGTCTCGTCTCCTCTTCTCCCCTTCCCTCCCCCTCCGCATCCCAGGATCAC
ACCGGTCAACGAGGGTTGGGGGGGTCCGGCACGGACCCAAAATAATAA

Protein Sequence : Show Sequence

>YP_009137119.1 envelope glycoprotein C [Human alphaherpesvirus 1]
MAPGRVGLAVVLWSLLWLGAGVSGGSETASTGPTITAGAVTNASEAPTSGSPGSAASPEVTPTSTPNPNN
VTQNKTTPTEPASPPTTPKPTSTPKSPPTSTPDPKPKNNTTPAKSGRPTKPPGPVWCDRRDPLARYGSRV
QIRCRFRNSTRMEFRLQIWRYSMGPSPPIAPAPDLEEVLTNITAPPGGLLVYDSAPNLTDPHVLWAEGAG
PGADPPLYSVTGPLPTQRLIIGEVTPATQGMYYLAWGRMDSPHEYGTWVRVRMFRPPSLTLQPHAVMEGQ
PFKATCTAAAYYPRNPVEFVWFEDDHQVFNPGQIDTQTHEHPDGFTTVSTVTSEAVGGQVPPRTFTCQMT
WHRDSVTFSRRNATGLALVLPRPTITMEFGVRHVVCTAGCVPEGVTFAWFLGDDPSPAAKSAVTAQESCD
HPGLATVRSTLPISYDYSEYICRLTGYPAGIPVLEHHGSHQPPPRDPTERQVIEAIEWVGIGIGVLAAGV
LVVTAIVYVVRTSQSRQRHRR

Molecule Role : Protective antigen
Molecule Role Annotation : Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
Related Vaccine(s): Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes simplex virus type 1 DNA vaccine encoding GC

13. UL44 from HSV-2

Gene Name : UL44 from HSV-2
Sequence Strain (Species/Organism) : Human alphaherpesvirus 2
NCBI Gene ID : 1487331
NCBI Protein GI : 820945196
Locus Tag : HHV2p31
Genbank Accession : KX574886
Protein Accession : YP_009137196
Taxonomy ID : 10310
Gene Starting Position : 97014
Gene Ending Position : 99335
Gene Strand (Orientation) : +
Protein Name : envelope glycoprotein C
Protein pI : 9.89
Protein Weight : 47108.15
Protein Length : 480
Protein Note : envelope glycoprotein C; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; the nonessential glycoprotein gC interacts with cell surface proteoglycans, whereas the essential glycoprotein gD is involved in stable secondary attachment

DNA Sequence : Show Sequence

>NC_001798.2:97014-99335 Human herpesvirus 2 strain HG52, complete genome
CATGGCCCTTGGACGGGTGGGCCTAGCCGTGGGCCTGTGGGGCCTGCTGTGGGTGGGTGTGGTCGTGGTG
CTGGCCAATGCCTCCCCCGGACGCACGATAACGGTGGGCCCGCGGGGGAACGCGAGCAATGCCGCCCCCT
CCGCGTCCCCGCGGAACGCATCCGCCCCCCGAACCACACCCACGCCCCCCCAACCCCGCAAGGCGACGAA
AAGTAAGGCCTCCACCGCCAAACCGGCCCCGCCCCCCAAGACCGGGCCCCCGAAGACATCCTCGGAGCCC
GTGCGATGCAACCGCCACGACCCGCTGGCCCGGTACGGCTCGCGGGTGCAAATCCGATGCCGGTTTCCCA
ACTCCACCCGCACGGAGTTCCGCCTCCAGATCTGGCGTTATGCCACGGCGACGGACGCCGAGATCGGAAC
GGCGCCTAGCTTAGAGGAGGTGATGGTAAACGTGTCGGCCCCGCCCGGGGGCCAACTGGTGTATGACAGC
GCCCCCAACCGAACGGACCCGCACGTGATCTGGGCGGAGGGCGCCGGCCCGGGCGCCAGCCCGCGGCTGT
ACTCGGTCGTCGGGCCGCTGGGTCGGCAGCGGCTCATCATCGAAGAGCTGACCCTGGAGACCCAGGGCAT
GTACTACTGGGTGTGGGGCCGGACGGACCGCCCGTCCGCGTACGGGACCTGGGTGCGCGTTCGCGTGTTC
CGCCCTCCGTCGCTGACCATCCACCCCCACGCGGTGCTGGAGGGCCAGCCGTTTAAGGCGACGTGCACGG
CCGCCACCTACTACCCGGGCAACCGCGCGGAGTTCGTCTGGTTCGAGGACGGTCGCCGGGTGTTCGATCC
GGCCCAGATACACACGCAGACGCAGGAGAACCCCGACGGCTTTTCCACCGTCTCCACCGTGACCTCCGCG
GCCGTCGGCGGCCAGGGCCCCCCGCGCACCTTCACCTGCCAGCTGACGTGGCACCGCGACTCCGTGTCGT
TCTCTCGGCGCAACGCCAGCGGCACGGCATCGGTGCTGCCGCGGCCAACCATCACCATGGAGTTTACGGG
CGACCATGCGGTCTGCACGGCCGGCTGTGTGCCCGAGGGGGTGACGTTTGCCTGGTTCCTGGGGGACGAC
TCCTCGCCGGCGGAGAAGGTGGCCGTCGCGTCCCAGACATCGTGCGGGCGCCCCGGCACCGCCACGATCC
GCTCCACCCTGCCGGTCTCGTACGAGCAGACCGAGTACATCTGCCGGCTGGCGGGATACCCGGACGGAAT
TCCGGTCCTAGAGCACCACGGCAGCCACCAGCCCCCGCCGCGGGACCCCACCGAGCGGCAGGTGATCCGG
GCGGTGGAGGGGGCGGGGATCGGAGTGGCTGTCCTTGTCGCGGTGGTTCTGGCCGGGACCGCGGTAGTGT
ACCTCACCCACGCCTCCTCGGTGCGCTATCGTCGGCTGCGGTAACTCCGGGGCCGGGCCCGGCCGCCGGT
TGTCTTCTTTTCCACCCCTTCCGTCCCCCGTACCCACCACACCCCACCCCACCCCCCCGCCGTCCCCCGG
GCGTTATAAGCCGCCGCACTCGCTTTTCCCACCGGAAAATCCTCGGCCCGATCCGAACGGCGCACGCCGC
GTGGGCTCCAAACGCCTCCGGAAGAGAGCGCCCCGCCCCGATATTCAAGCCCGCGGTGGTGCTATGGCTT
TCCGTGCTTCGGGACCCGCCTACCAGCCCCTCGCCCCCGCGGCCTCCCCGGCGCGGGCTCGTGTTCCGGC
CGTGGCCTGGATCGGCGTCGGAGCGATCGTCGGGGCCTTTGCGCTCGTCGCCGCGTTGGTTCTCGTACCC
CCTCGGTCCTCGTGGGGACTCTCGCCGTGCGACAGCGGCTGGCAGGAATTCAACGCGGGATGCGTCGCGT
GGGACCCCACCCCCGTCGAGCACGAGCAGGCGGTCGGCGGCTGCAGCGCGCCGGCCACCCTTATCCCCCG
TGCGGCCGCCAAGCACCTGGCCGCTCTGACACGCGTCCAGGCGGAGAGATCGTCGGGTTACTGGTGGGTG
AACGGAGACGGCATCCGGACCTGTCTGAGACTCGTCGACAGCGTCAGTGGCATCGACGAGTTTTGCGAGG
AGCTCGCGATCCGCATATGCTACTACCCACGAAGCCCCGGCGGGTTTGTCCGCTTCGTAACTTCGATACG
TAACGCCCTGGGGTTGCCGTGAGGCGCGCGTCCGACGGTCCCGCTTCTCGCCTCTCTTCTTCCCCCACCC
CACCCACCGACCAACGACGGCGTTTGGCCAATACCCTCCTTTTTTCTTTTTCTCTTCCCCCCCCCCCCAA
AAAAAACAATAA

Protein Sequence : Show Sequence

>YP_009137196.1 envelope glycoprotein C [Human alphaherpesvirus 2]
MALGRVGLAVGLWGLLWVGVVVVLANASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATK
SKASTAKPAPPPKTGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTEFRLQIWRYATATDAEIGT
APSLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLIIEELTLETQGM
YYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDP
AQIHTQTQENPDGFSTVSTVTSAAVGGQGPPRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTG
DHAVCTAGCVPEGVTFAWFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGI
PVLEHHGSHQPPPRDPTERQVIRAVEGAGIGVAVLVAVVLAGTAVVYLTHASSVRYRRLR

Molecule Role : Protective antigen
Molecule Role Annotation : Balb/c mice were immunized with either pgB-2 or pgC-2 plasmids intramuscularly (IM) or intradermally (ID). IM immunization of latently infected guinea pigs with a combined gB-2 and gC-2 plasmid vaccine significantly reduced the number of subsequent HSV-2 recurrences (Mester et al., 1999).
Another study also found that antibodies produced by gC-2 immunization blocked the interaction between gC-2 and complement C3b, and passive transfer of gC-2 antibody protected complement-intact mice but not C3 knockout mice against HSV-2 challenge (Awasthi et al., 2011). Therefore, gC-2 antibody is effective, at least in part, because it prevents HSV-2 evasion from complement.

14. US4

Gene Name : US4
Sequence Strain (Species/Organism) : Human alphaherpesvirus 2
VO ID : VO_0011102
NCBI Gene ID : 1487356
NCBI Protein GI : 820945216
Locus Tag : HHV2p11
Genbank Accession : JN561323
Protein Accession : YP_009137216
Taxonomy ID : 10310
Gene Starting Position : 137881
Gene Ending Position : 140058
Gene Strand (Orientation) : +
Protein Name : envelope glycoprotein G
Protein pI : 8.54
Protein Weight : 68471.88
Protein Length : 699
Protein Note : gD family

DNA Sequence : Show Sequence

>NC_001798.2:137881-140058 Human herpesvirus 2 strain HG52, complete genome
CATGCACGCCATCGCTCCCAGGTTGCTTCTTCTTTTTGTTCTTTCTGGTCTTCCGGGGACACGCGGCGGG
TCGGGTGTCCCCGGACCAATTAATCCCCCCAACAGCGATGTTGTTTTCCCGGGAGGTTCCCCCGTGGCTC
AATATTGTTATGCCTATCCCCGGTTGGACGATCCCGGGCCCTTGGGTTCCGCGGACGCCGGGCGGCAAGA
CCTGCCCCGGCGCGTCGTCCGTCACGAGCCCCTGGGCCGCTCGTTCCTCACGGGGGGGCTGGTTTTGCTG
GCGCCGCCGGTACGCGGATTTGGCGCACCCAACGCAACGTATGCGGCCCGTGTGACGTACTACCGGCTCA
CCCGCGCCTGCCGTCAGCCCATCCTCCTTCGGCAGTATGGAGGGTGTCGCGGCGGCGAGCCGCCGTCCCC
AAAGACGTGCGGGTCGTACACGTACACGTACCAGGGCGGCGGGCCTCCGACCCGGTACGCTCTCGTAAAT
GCTTCCCTGCTGGTGCCGATCTGGGACCGCGCCGCGGAGACATTCGAGTACCAGATCGAACTCGGCGGCG
AGCTGCACGTGGGTCTGTTGTGGGTAGAGGTGGGCGGGGAGGGCCCCGGCCCCACCGCCCCCCCACAGGC
GGCGCGTGCGGAGGGCGGCCCGTGCGTCCCCCCGGTCCCCGCGGGCCGCCCGTGGCGCTCGGTGCCCCCG
GTATGGTATTCCGCCCCCAACCCCGGGTTTCGTGGCCTGCGTTTCCGGGAGCGCTGTCTGCCCCCACAGA
CGCCCGCCGCCCCCAGCGACCTACCACGCGTCGCTTTTGCTCCCCAGAGCCTGCTGGTGGGGATTACGGG
CCGCACGTTTATTCGGATGGCACGACCCACGGAAGACGTCGGGGTCCTGCCGCCCCATTGGGCCCCCGGG
GCCCTAGATGACGGTCCGTACGCCCCCTTCCCACCCCGCCCGCGGTTTCGACGCGCCCTGCGGACAGACC
CCGAGGGGGTCGACCCCGACGTTCGGGCCCCCCGAACCGGGCGGCGCCTCATGGCCTTGACCGAGGACAC
GTCCTCCGATTCGCCTACGTCCGCTCCGGAGAAGACGCCCCTCCCTGTGTCGGCCACCGCCATGGCACCC
TCAGTCGACCCAAGCGCGGAACCGACCGCCCCCGCAACCACTACTCCCCCCGACGAGATGGCCACACAAG
CCGCAACGGTCGCCGTTACGCCGGAGGAAACGGCAGTCGCCTCCCCGCCCGCGACTGCATCCGTGGAGTC
GTCGCCACTCCCCGCCGCGGCGGCGGCAACGCCCGGGGCCGGGCACACGAACACCAGCAGCGCCTCCGCA
GCGAAAACGCCCCCCACCACACCAGCCCCCACGACCCCCCCGCCCACGTCTACCCACGCGACCCCCCGCC
CCACGACTCCGGGGCCCCAAACAACCCCTCCCGGACCCGCAACCCCGGGTCCGGTGGGCGCCTCCGCCGC
GCCCACGGCCGATTCCCCCCTCACCGCCTCGCCCCCCGCTACCGCGCCGGGGCCCTCGGCCGCCAACGTT
TCGGTCGCCGCGACCACCGCCACGCCCGGAACCCGGGGCACCGCCCGTACCCCCCCAACGGACCCAAAGA
CGCACCCACACGGACCCGCGGACGCTCCCCCCGGCTCGCCAGCCCCCCCACCCCCCGAACATCGCGGCGG
ACCCGAGGAGTTTGAGGGCGCCGGGGACGGCGAACCCCCCGAGGACGACGACAGCGCCACCGGCCTCGCC
TTCCGAACTCCGAACCCCAACAAACCACCCCCCGCGCGCCCCGGGCCCATCCGCCCCACGCTCCCGCCAG
GAATTCTTGGGCCGCTCGCCCCCAACACGCCTCGCCCCCCCGCCCAAGCTCCCGCTAAGGACATGCCCTC
GGGCCCCACACCCCAACACATCCCCCTGTTCTGGTTCCTAACGGCCTCCCCTGCTCTAGATATCCTCTTT
ATCATCAGCACCACCATCCACACGGCGGCGTTCGTTTGTCTGGTCGCCTTGGCAGCACAACTTTGGCGCG
GCCGGGCGGGGCGCAGGCGATACGCGCACCCGAGCGTGCGTTACGTATGTCTGCCACCCGAGCGGGATTA
GGGGGTGGGGGTGGGGGGCGAGAAACGATGAAGGACGGGAAAGGGAACAGCGACCAAATGTCACGATAAG
AACAATAA

Protein Sequence : Show Sequence

>YP_009137216.1 envelope glycoprotein G [Human alphaherpesvirus 2]
MHAIAPRLLLLFVLSGLPGTRGGSGVPGPINPPNSDVVFPGGSPVAQYCYAYPRLDDPGPLGSADAGRQD
LPRRVVRHEPLGRSFLTGGLVLLAPPVRGFGAPNATYAARVTYYRLTRACRQPILLRQYGGCRGGEPPSP
KTCGSYTYTYQGGGPPTRYALVNASLLVPIWDRAAETFEYQIELGGELHVGLLWVEVGGEGPGPTAPPQA
ARAEGGPCVPPVPAGRPWRSVPPVWYSAPNPGFRGLRFRERCLPPQTPAAPSDLPRVAFAPQSLLVGITG
RTFIRMARPTEDVGVLPPHWAPGALDDGPYAPFPPRPRFRRALRTDPEGVDPDVRAPRTGRRLMALTEDT
SSDSPTSAPEKTPLPVSATAMAPSVDPSAEPTAPATTTPPDEMATQAATVAVTPEETAVASPPATASVES
SPLPAAAAATPGAGHTNTSSASAAKTPPTTPAPTTPPPTSTHATPRPTTPGPQTTPPGPATPGPVGASAA
PTADSPLTASPPATAPGPSAANVSVAATTATPGTRGTARTPPTDPKTHPHGPADAPPGSPAPPPPEHRGG
PEEFEGAGDGEPPEDDDSATGLAFRTPNPNKPPPARPGPIRPTLPPGILGPLAPNTPRPPAQAPAKDMPS
GPTPQHIPLFWFLTASPALDILFIISTTIHTAAFVCLVALAAQLWRGRAGRRRYAHPSVRYVCLPPERD

Molecule Role : Protective antigen
Molecule Role Annotation : In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 (Grabowska et al., 2000).
Related Vaccine(s): Herpes simplex virus type 2 vaccine using phage displaying GG protein

15. US5

Gene Name : US5
Sequence Strain (Species/Organism) : Human alphaherpesvirus 1
VO ID : VO_0011098
NCBI Gene ID : 2703406
NCBI Protein GI : 820945295
Locus Tag : HHV1gp00p10
Genbank Accession : AY240646
Protein Accession : YP_009137140
Taxonomy ID : 10298
Gene Starting Position : 137598
Gene Ending Position : 141051
Gene Strand (Orientation) : +
Protein Name : mRNA
Protein pI : 8.94
Protein Weight : 8366.08
Protein Length : 92

DNA Sequence : Show Sequence

>NC_001806.2:137598-141051 Human herpesvirus 1 strain 17, complete genome
TTAAATACATGCCCGGGACCCATGAAGCATGCGCGACTTCCGGGCCTCAGAACCCACCCGAAACGGCCAA
CGGACGTCTGAGCCAGGCCTGGCTATCCGGAGAAACAGCACACGACTTGGCGTTCTGTGTGTCGCGATGT
CTCTGCGCGCAGTCTGGCATCTGGGGCTTTTGGGAAGCCTCGTGGGGGCTGTTCTTGCCGCCACCCATCG
GGGACCTGCGGCCAACACAACGGACCCCTTAACGCACGCCCCAGTGTCCCCTCACCCCAGCCCCCTGGGG
GGCTTTGCCGTCCCCCTCGTAGTCGGTGGGCTGTGCGCCGTAGTCCTGGGGGCGGCATGTCTGCTTGAGC
TCCTGCGTCGTACGTGCCGCGGGTGGGGGCGTTACCATCCCTACATGGACCCAGTTGTCGTATAATTTCC
CCCCCCCCCCCCCTTCTCCGCGTGGGTGATGTCGGGTCCAAACTCCCGACACCACCAGCTGGCATGGTAT
AAATCACCGGTGCGCCCCCCAAACCATGTCCGGCAGGGGGATGGGGGGGCGAATGCGGAGGGCACCCAAC
AACACCGGGCTAACCAGGAAATCCGTGGCCCCGGCCCCCAATAAAGATCGCGGTAGCCCGGCCGTGTGAC
ACTATCGTCCATACCGACCACACCGACGAATCCCCCAAGGGGGAGGGGCCATTTTACGAGGAGGAGGGGT
ATAACAAAGTCTGTCTTTAAAAAGCAGGGGTTAGGGAGTTGTTCGGTCATAAGCTTCAGCGCGAACGACC
AACTACCCCGATCATCAGTTATCCTTAAGGTCTCTTTTGTGTGGTGCGTTCCGGTATGGGGGGGGCTGCC
GCCAGGTTGGGGGCCGTGATTTTGTTTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCT
TGGTGGATGCCTCTCTCAAGATGGCCGACCCCAATCGCTTTCGCGGCAAAGACCTTCCGGTCCTGGACCA
GCTGACCGACCCTCCGGGGGTCCGGCGCGTGTACCACATCCAGGCGGGCCTACCGGACCCGTTCCAGCCC
CCCAGCCTCCCGATCACGGTTTACTACGCCGTGTTGGAGCGCGCCTGCCGCAGCGTGCTCCTAAACGCAC
CGTCGGAGGCCCCCCAGATTGTCCGCGGGGCCTCCGAAGACGTCCGGAAACAACCCTACAACCTGACCAT
CGCTTGGTTTCGGATGGGAGGCAACTGTGCTATCCCCATCACGGTCATGGAGTACACCGAATGCTCCTAC
AACAAGTCTCTGGGGGCCTGTCCCATCCGAACGCAGCCCCGCTGGAACTACTATGACAGCTTCAGCGCCG
TCAGCGAGGATAACCTGGGGTTCCTGATGCACGCCCCCGCGTTTGAGACCGCCGGCACGTACCTGCGGCT
CGTGAAGATAAACGACTGGACGGAGATTACACAGTTTATCCTGGAGCACCGAGCCAAGGGCTCCTGTAAG
TACGCCCTCCCGCTGCGCATCCCCCCGTCAGCCTGCCTCTCCCCCCAGGCCTACCAGCAGGGGGTGACGG
TGGACAGCATCGGGATGCTGCCCCGCTTCATCCCCGAGAACCAGCGCACCGTCGCCGTATACAGCTTGAA
GATCGCCGGGTGGCACGGGCCCAAGGCCCCATACACGAGCACCCTGCTGCCCCCGGAGCTGTCCGAGACC
CCCAACGCCACGCAGCCAGAACTCGCCCCGGAAGACCCCGAGGATTCGGCCCTCTTGGAGGACCCCGTGG
GGACGGTGGCGCCGCAAATCCCACCAAACTGGCACATACCGTCGATCCAGGACGCCGCGACGCCTTACCA
TCCCCCGGCCACCCCGAACAACATGGGCCTGATCGCCGGCGCGGTGGGCGGCAGTCTCCTGGCAGCCCTG
GTCATTTGCGGAATTGTGTACTGGATGCGCCGCCACACTCAAAAAGCCCCAAAGCGCATACGCCTCCCCC
ACATCCGGGAAGACGACCAGCCGTCCTCGCACCAGCCCTTGTTTTACTAGATACCCCCCCTTAATGGGTG
CGGGGGGGTCAGGTCTGCGGGGTTGGGATGGGACCTTAACTCCATATAAAGCGAGTCTGGAAGGGGGGAA
AGGTGGACAGTCGATAAGTCGGTAGCGGGGGACGCGCACCTGTTCCGCCTGTCGCACCCACAGCTTTTTT
TGCGAACCGTCCCGTTCCGGGATGCCGTGCCGCCCGTTGCAGGGCCTGGTGCTCGTGGGCCTCTGGGTCT
GTGCCACCAGCCTGGTTGTCCGTGGCCCCACGGTCAGTCTGGTATCAAACTCATTTGTGGACGCCGGGGC
CTTGGGGCCCGACGGCGTAGTGGAGGAAGACCTGCTTATTCTCGGGGAGCTTCGCTTTGTGGGGGACCAG
GTCCCCCACACCACCTACTACGATGGGGGCGTAGAGCTGTGGCACTACCCCATGGGACACAAATGCCCAC
GGGTCGTGCATGTCGTCACGGTGACCGCGTGCCCACGTCGCCCCGCCGTGGCATTCGCCCTGTGTCGCGC
GACCGACAGCACTCACAGCCCCGCATATCCCACCCTGGAGCTCAATCTGGCCCAACAGCCGCTTTTGCGG
GTCCAGAGGGCAACGCGGGACTATGCCGGGGTGTACGTGTTACGCGTATGGGTCGGTGACGCGCCAAACG
CCAGCCTGTTTGTCCTGGGGATGGCCATAGCCGCCGAAGGGACTCTGGCGTACAACGGCTCGGCCTATGG
CTCCTGCGACCCGAAACTGCTTCCGTCTTCGGCCCCGCGTCTGGCCCCGGCGAGCGTATACCAACCCGCC
CCTAACCAGGCCTCCACCCCCTCGACCACCACCTCCACCCCCTCGACCACCATCCCCGCTCCCTCGACCA
CCATCCCCGCTCCCCAAGCATCGACCACGCCCTTCCCCACGGGAGATCCAAAACCACAACCTCCCGGGGT
CAACCACGAACCCCCATCTAATGCCACGCGAGCGACCCGCGACTCGCGATACGCGCTAACGGTGACCCAG
ATAATCCAGATAGCCATCCCCGCGTCCATCATAGCCCTGGTGTTTCTGGGGAGCTGTATTTGCTTTATAC
ACAGATGTCAACGCCGCTACCGACGCTCCCGTCGCCCGATTTACAGCCCCCAGATGCCCACGGGCATCTC
ATGCGCGGTGAACGAAGCGGCCATGGCCCGCCTCGGAGCCGAGCTCAAATCGCATCCGAGCACCCCCCCC
AAATCCCGGCGCCGGTCGTCACGCACGCCAATGCCCTCCCTGACGGCCATCGCCGAAGAGTCGGAGCCCG
CTGGGGCGGCTGGGCTTCCGACGCCCCCCGTGGACCCCACGACACCCACCCCAACGCCTCCCCTGTTGGT
ATAGGTCCACGGCCACTGGCCGGGAGCACCACATAACCGACCGCAGTCCCTGAGTTGGGAATAAACCGGT
ATTATTTACCTATATCCGTGTATG

Protein Sequence : Show Sequence

>YP_009137140.1 envelope glycoprotein J [Human alphaherpesvirus 1]
MSLRAVWHLGLLGSLVGAVLAATHRGPAANTTDPLTHAPVSPHPSPLGGFAVPLVVGGLCAVVLGAACLL
ELLRRTCRGWGRYHPYMDPVVV

Molecule Role : Protective antigen
Molecule Role Annotation : BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 (Jamali et al., 2009).
Related Vaccine(s): Herpes simplex virus type 1 DNA vaccine encoding GD

16. US6

Gene Name : US6
Sequence Strain (Species/Organism) : Human alphaherpesvirus 2
VO ID : VO_0011096
NCBI Gene ID : 1487358
NCBI Protein GI : 820945218
Locus Tag : HHV2p09
Genbank Accession : KX574902
Protein Accession : YP_009137218
Taxonomy ID : 10310
Gene Starting Position : 141015
Gene Ending Position : 143587
Gene Strand (Orientation) : +
Protein Name : envelope glycoprotein D
Protein pI : 7.84
Protein Weight : 40611.38
Protein Length : 393
Protein Note : gD family

DNA Sequence : Show Sequence

>NC_001798.2:141015-143587 Human herpesvirus 2 strain HG52, complete genome
CATGGGGCGTTTGACCTCCGGCGTCGGGACGGCGGCCCTGCTAGTTGTCGCGGTGGGACTCCGCGTCGTC
TGCGCCAAATACGCCTTAGCAGACCCCTCGCTTAAGATGGCCGATCCCAATCGATTTCGCGGGAAGAACC
TTCCGGTTTTGGACCAGCTGACCGACCCCCCCGGGGTGAAGCGTGTTTACCACATTCAGCCGAGCCTGGA
GGACCCGTTCCAGCCCCCCAGCATCCCGATCACTGTGTACTACGCAGTGCTGGAACGTGCCTGCCGCAGC
GTGCTCCTACATGCCCCATCGGAGGCCCCCCAGATCGTGCGCGGGGCTTCGGACGAGGCCCGAAAGCACA
CGTACAACCTGACCATCGCCTGGTATCGCATGGGAGACAATTGCGCTATCCCCATCACGGTTATGGAATA
CACCGAGTGCCCCTACAACAAGTCGTTGGGGGTCTGCCCCATCCGAACGCAGCCCCGCTGGAGCTACTAT
GACAGCTTTAGCGCCGTCAGCGAGGATAACCTGGGATTCCTGATGCACGCCCCCGCCTTCGAGACCGCGG
GTACGTACCTGCGGCTAGTGAAGATAAACGACTGGACGGAGATCACACAATTTATCCTGGAGCACCGGGC
CCGCGCCTCCTGCAAGTACGCTCTCCCCCTGCGCATCCCCCCGGCAGCGTGCCTCACCTCGAAGGCCTAC
CAACAGGGCGTGACGGTCGACAGCATCGGGATGCTACCCCGCTTTATCCCCGAAAACCAGCGCACCGTCG
CCCTATACAGCTTAAAAATCGCCGGGTGGCACGGCCCCAAGCCCCCGTACACCAGCACCCTGCTGCCGCC
GGAGCTGTCCGACACCACCAACGCCACGCAACCCGAACTCGTTCCGGAAGACCCCGAGGACTCGGCCCTC
TTAGAGGATCCCGCCGGGACGGTGTCTTCGCAGATCCCCCCAAACTGGCACATCCCGTCGATCCAGGACG
TCGCGCCGCACCACGCCCCCGCCGCCCCCAGCAACCCGGGCCTGATCATCGGCGCGCTGGCCGGCAGTAC
CCTGGCGGTGCTGGTCATCGGCGGTATTGCGTTTTGGGTACGCCGCCGCGCTCAGATGGCCCCCAAGCGC
CTACGTCTCCCCCACATCCGGGATGACGACGCGCCCCCCTCGCACCAGCCATTGTTTTACTAGAGGAGTT
TCCCCGCTCCCGTGTACCTCTGGGCCCGTGTGGGAGGGTGGCTGGGGTATTTGGGTGGGACTTGGACTCC
GCATAAAGGGAGTCTCGAAGGAGGGAAACTAGGACAGTTCATAGGCCGGGAGCGTGGGGCGCGCACCGCT
GTCCCGACGATTAGCCACCGCGCCCACAGCCACCTCGACCCGTCCGATCCCGGTATGCCCGGCCGCTCGC
TGCAGGGCCTGGCGATCCTGGGCCTGTGGGTCTGCGCCACCGGCCTGGTCGTCCGCGGCCCCACGGTCAG
TCTGGTCTCAGACTCACTCGTGGATGCCGGGGCCGTGGGGCCCCAGGGCTTCGTGGAAGAGGACCTGCGT
GTTTTCGGGGAGCTTCATTTTGTGGGGGCCCAGGTCCCCCACACAAACTACTACGACGGCATCATCGAGC
TGTTTCACTACCCCCTGGGGAACCACTGCCCCCGCGTTGTACACGTGGTCACACTGACCGCATGCCCCCG
CCGCCCCGCCGTGGCGTTCACCTTGTGTCGCTCGACGCACCACGCCCACAGCCCCGCCTATCCGACCCTG
GAGCTGGGTCTGGCGCGGCAGCCGCTTCTGCGGGTTCGAACGGCAACGCGCGACTATGCCGGTCTGTATG
TCCTGCGCGTATGGGTCGGCAGCGCGACGAACGCCAGCCGGTTTGTTTTGGGGGTGGCGCTCTCTGCCAA
CGGGACGTTTGTGTATAACGGCTCGGACTACGGCTCCTGCGATCCGGCGCAGCTTCCCTTTTCGGCCCCG
CGCCTGGGACCCTCGAGCGTATACACCCCCGGAGCCTCCCGACCCACCCCTCCACGGACAACGACACCCC
CGTCCTCCCCCCGAGACCCGACCCCCGCCCCCGGGGACACAGGGACGCCCGCGCCCGCGAGCGGCGAGAT
AGCCCCGCCCAATTCCACGCGATCGGCCAGCGAATCGAGACACAGGCTAACCGTAGCCCAGGTAATCCAG
ATCGCCATACCGGCGTCCATCATCGCCTTTGTGTTTCTGGGCAGCTGTATCTGCTTCATCCATAGATGCC
AGCGCCGATACAGGCGCCCCCGCGGCCAGATTTACAACCCCGGGGGCGTTTCCTGCGCGGTCAACGAGGC
GGCCATGGCCCGCCTCGGAGCCGAGCTGCGATCCCACCCAAACACCCCCCCCAAACCCCGACGCCGTTCG
TCGTCGTCCACGACCATGCCTTCCCTAACGTCGATAGCTGAGGAATCGGAGCCAGGTCCAGTCGTGCTGC
TGTCCGTCAGTCCTCGGCCCCGCAGTGGCCCGACGGCCCCCCAAGAGGTCTAGGTCCAAGCGGGCCGTTC
GGCAGGCCCGCCCCACCGCCCCCATCGTGGTTATTTCCCCCCCCCCCCAATAA

Protein Sequence : Show Sequence

>YP_009137218.1 envelope glycoprotein D [Human alphaherpesvirus 2]
MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLE
DPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEY
TECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPP
ELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGST
LAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY

Molecule Role : Protective antigen
Molecule Role Annotation : The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome. Expression of gD2 in cells infected with the recombinant Oka strain VZV (ROka-gD2) was confirmed by antibody staining of fixed cells and by immunoblot analysis. Forty days after the third inoculation, guinea pigs were challenged intravaginally with HSV-2. Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001) (Heineman et al., 1995).

17. US7

Gene Name : US7
Sequence Strain (Species/Organism) : Human herpesvirus 1 strain McKrae
NCBI Protein GI : 388525000
Other Database IDs : CDD:223033
CDD:279953
Taxonomy ID : 10298
Gene Strand (Orientation) : ?
Protein Name : gI
Protein pI : 9.08
Protein Weight : 40934
Protein Length : 462
Protein Note : type: 1

Protein Sequence : Show Sequence

>AFK50416.1 gI [Human alphaherpesvirus 1]
MQGLVLVGLWVCATSLVVRGPTVSLVSNSFVDAGALGPDGVVEEDLLILGELRFVGDQVPHTTYYDGVVE
LWHYPMGHKCPRVVHVVTVTACPRRPAVAFALCRATDNTHSPAYPTLELNLAQQPLLRVRRATRDYAGVY
VLRVWVVDAPNASLFVLGMAIAAEGTLAYNGSAHGSCDPKLLPYSAPRLAPASVYQPAPNPASTPSTTTS
TPSTTTSTPSTTTSTPSTTTSTPSTTTSTPSTTTSTPSTTIPAPQASTTPFPTGDPKPQPHGVNHEPPSN
ATRATRDSRYALTVTQIIQIAIPASIIALVFLGSCICFIHRCQRRYRRSRRPIYNPQIPTGISCAVNEAA
MARLGAELKSHPSTPPKSRRRSSRTPMPSLTAIAEESEPAGAAGLPTPPVDPTTSTPTPPLLV

Molecule Role : Protective antigen
Related Vaccine(s): Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP

18. US8

Gene Name : US8
Sequence Strain (Species/Organism) : Human alphaherpesvirus 1
VO ID : VO_0011104
NCBI Gene ID : 2703448
NCBI Protein GI : 820945298
Locus Tag : HHV1gp00p07
Genbank Accession : AJ626470
Protein Accession : YP_009137143
Taxonomy ID : 10298
Gene Starting Position : 141142
Gene Ending Position : 143696
Gene Strand (Orientation) : +
Protein Name : mRNA
Protein pI : 6.08
Protein Weight : 54133.1
Protein Length : 550

DNA Sequence : Show Sequence

>NC_001806.2:141142-143696 Human herpesvirus 1 strain 17, complete genome
GCATTTAAGGCGTTGTTGTGTTGACTTTGCCTCTTCTGGCGGGTTGGTGCGGTGCTGTTTGTTGGGCTCC
CATTTTACCCGAAGATCGGCTGCTATCCCCGGGACATGGATCGCGGGGCGGTGGTGGGGTTTCTTCTCGG
TGTTTGTGTTGTATCGTGCTTGGCGGGAACGCCCAAAACGTCCTGGAGACGGGTGAGTGTCGGCGAGGAC
GTTTCGTTGCTTCCAGCTCCGGGGCCTACGGGGCGCGGCCCGACCCAGAAACTACTATGGGCCGTGGAAC
CCCTGGATGGGTGCGGCCCCTTACACCCGTCGTGGGTCTCGCTGATGCCCCCCAAGCAGGTGCCCGAGAC
GGTCGTGGATGCGGCGTGCATGCGCGCTCCGGTCCCGCTGGCGATGGCGTACGCCCCCCCGGCCCCATCT
GCGACCGGGGGTCTACGAACGGACTTCGTGTGGCAGGAGCGCGCGGCCGTGGTTAACCGGAGTCTGGTTA
TTCACGGGGTCCGAGAGACGGACAGCGGCCTGTATACCCTGTCCGTGGGCGACATAAAGGACCCGGCTCG
CCAAGTGGCCTCGGTGGTCCTGGTGGTGCAACCGGCCCCAGTTCCGACCCCACCCCCGACCCCAGCCGAT
TACGACGAGGATGACAATGACGAGGGCGAGGACGAAAGTCTCGCCGGCACTCCCGCCAGCGGGACCCCCC
GGCTCCCGCCTCCCCCCGCCCCCCCGAGGTCTTGGCCCAGCGCCCCCGAAGTCTCACATGTGCGTGGGGT
GACCGTGCGTATGGAGACTCCGGAAGCTATCCTGTTTTCCCCCGGGGAGACGTTCAGCACGAACGTCTCC
ATCCATGCCATCGCCCACGACGACCAGACCTACTCCATGGACGTCGTCTGGTTGAGGTTCGACGTGCCGA
CCTCGTGTGCCGAGATGCGAATATACGAATCGTGTCTGTATCACCCGCAGCTCCCAGAATGTCTGTCCCC
GGCCGACGCGCCGTGCGCCGCGAGTACGTGGACGTCTCGCCTGGCCGTCCGCAGCTACGCGGGGTGTTCC
AGAACAAACCCCCCACCGCGCTGTTCGGCCGAGGCTCACATGGAGCCCGTCCCGGGGCTGGCGTGGCAGG
CGGCCTCCGTCAATCTGGAGTTCCGGGACGCGTCCCCACAACACTCCGGCCTGTATCTGTGTGTGGTGTA
CGTCAACGACCATATTCACGCCTGGGGCCACATTACCATCAGCACCGCGGCGCAGTACCGGAACGCGGTG
GTGGAACAGCCCCTCCCACAGCGCGGCGCGGATTTGGCCGAGCCCACCCACCCGCACGTCGGGGCCCCTC
CCCACGCGCCCCCAACCCACGGCGCCCTGCGGTTAGGGGCGGTGATGGGGGCCGCCCTGCTGCTGTCTGC
ACTGGGGTTGTCGGTGTGGGCGTGTATGACCTGTTGGCGCAGGCGTGCCTGGCGGGCGGTTAAAAGCAGG
GCCTCGGGTAAGGGGCCCACGTACATTCGCGTGGCCGACAGCGAGCTGTACGCGGACTGGAGCTCGGACA
GCGAGGGAGAACGCGACCAGGTCCCGTGGCTGGCCCCCCCGGAGAGACCCGACTCTCCCTCCACCAATGG
ATCCGGCTTTGAGATCTTATCACCAACGGCTCCGTCTGTATACCCCCGTAGCGATGGGCATCAATCTCGC
CGCCAGCTCACAACCTTTGGATCCGGAAGGCCCGATCGCCGTTACTCCCAGGCCTCCGATTCGTCCGTCT
TCTGGTAAGGCGCCCCATCCCGAGGCCCCACGTCGGTCGCCGAACTGGGCGACCGCCGGCGAGGTGGACG
TCGGAGACGAGCTAATCGCGATTTCCGACGAACGCGGACCCCCCCGACATGACCGCCCGCCCCTCGCCAC
GTCGACCGCGCCCTCGCCACACCCGCGACCCCCGGGCTACACGGCCGTTGTCTCCCCGATGGCCCTCCAG
GCTGTCGACGCCCCCTCCCTGTTTGTCGCCTGGCTGGCCGCTCGGTGGCTCCGGGGGGCTTCCGGCCTGG
GGGCCGTCCTGTGTGGGATTGCGTGGTATGTGACGTCAATTGCCCGAGGCGCATAAAGGGCCGGTGGTCC
GCCTAGCCGCAGCAAATTAAAAATCGTGAGTCACAGCGACCGCAACTTCCCACCCGGAGCTTTCTTCCGG
CCTCGATGACGTCCCGGCTCTCCGATCCCAACTCCTCAGCGCGATCCGACATGTCCGTGCCGCTTTATCC
CACGGCCTCGCCAGTTTCGGTCGAAGCCTACTACTCGGAAAGCGAAGACGAGGCGGCCAACGACTTCCTC
GTACGCATGGGCCGCCAACAGTCGGTATTAAGGCGTCGACGCAGACGCACCCGCTGCGTCGGCATGGTGA
TCGCCTGTCTCCTCGTGGCCGTTCTGTCGGGCGGATTTGGGGCGCTCCTGATGTGGCTGCTCCGCTAAAA
GACCGCATCGACACGCGCGTCCTTCTTGTCGTCTCTCTTCCCCCCCATCACCCCGCAATTTGCACCCAGC
CTTTAACTACATTAAATTGGGTTCGATTGGCAATG

Protein Sequence : Show Sequence

>YP_009137143.1 envelope glycoprotein E [Human alphaherpesvirus 1]
MDRGAVVGFLLGVCVVSCLAGTPKTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLWAVEPLDGCGPLHPSW
VSLMPPKQVPETVVDAACMRAPVPLAMAYAPPAPSATGGLRTDFVWQERAAVVNRSLVIHGVRETDSGLY
TLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDEDDNDEGEDESLAGTPASGTPRLPPPPAPPRSW
PSAPEVSHVRGVTVRMETPEAILFSPGETFSTNVSIHAIAHDDQTYSMDVVWLRFDVPTSCAEMRIYESC
LYHPQLPECLSPADAPCAASTWTSRLAVRSYAGCSRTNPPPRCSAEAHMEPVPGLAWQAASVNLEFRDAS
PQHSGLYLCVVYVNDHIHAWGHITISTAAQYRNAVVEQPLPQRGADLAEPTHPHVGAPPHAPPTHGALRL
GAVMGAALLLSALGLSVWACMTCWRRRAWRAVKSRASGKGPTYIRVADSELYADWSSDSEGERDQVPWLA
PPERPDSPSTNGSGFEILSPTAPSVYPRSDGHQSRRQLTTFGSGRPDRRYSQASDSSVFW

Molecule Role : Protective antigen
Molecule Role Annotation : Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
Additional Molecule Role : Virmugen
Additional Molecule Role Annotation : An HSV-1 gE (Us8) deletion strain, NS-gEnull, was used as a live attenuated vaccine. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice (Brittle et al., 2008).
Related Vaccine(s): GSK1437173A , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes simplex virus type 1 DNA vaccine encoding GE

III. Vaccine Related Host Genes

1. IgG

Gene Name : IgG
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16059
Genbank Accession : AF010213
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 881411
Gene Ending Position : 914690
Gene Strand (Orientation) : +
Protein Name : immunoglobulin heavy chain (V7183 family)
Protein Note : Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)

DNA Sequence : Show Sequence

>gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
ACAAGCACAGTGCAAATTTCTGTCACCCTG

Molecule Role : Vaximmutor
Additional Molecule Role : Vaximmutor
Related Vaccine(s): Herpes simplex virus 2 ICP0 mutant vaccine

2. Ighv1-9

Gene Name : Ighv1-9
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 668478
Genbank Accession : AC073561
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 114583568
Gene Ending Position : 114583861
Protein Name : immunoglobulin heavy variable V1-9
Protein Note : Also known as Igg2a; Gm16697

DNA Sequence : Show Sequence

>gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
CTGCAGCTGAACCT

Molecule Role : Vaximmutor
Related Vaccine(s): Herpes simplex virus type 1 DNA vaccine encoding GE

IV. Vaccine Information

1. GSK1437173A

a. Product Name:

Herpes Zoster vaccine GSK1437173A

b. Vaccine Ontology ID:

VO_0004598

c. Type:

Subunit vaccine

d. Status:

Clinical trial

e. Antigen

Glycoprotein E (gE) (Chlibek et al., 2013)

f. Gene Engineering of US8

Type: Recombinant protein preparation
Description:
Detailed Gene Information: Click here.

g. Immunization Route

Intramuscular injection (i.m.)

h. Baboon Response

Vaccination Protocol: This project was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline (Chlibek et al., 2013).
Vaccine Immune Response Type: VO_0003057
Immune Response: Cell-mediated and humoral immune responses immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE. gE/AS01B induced stronger immune responses than gE/AS01E (Chlibek et al., 2013).
Side Effects: No vaccine-related severe adverse events were reported, and solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom (Chlibek et al., 2013).

2. Herpes simplex virus 1 gD mutant vaccine

a. Product Name:

KOS-gDA3C

b. Vaccine Ontology ID:

VO_0002970

c. Type:

Live, attenuated vaccine

d. Status:

Research

e. Host Species as Laboratory Animal Model:

Mouse

f. Gene Engineering of gD

Type: Gene mutation
Description: This gD mutant is from human herpesvirus 1 (Awasthi et al., 2008).
Detailed Gene Information: Click here.

g. Immunization Route

Flank scratch

h. Mouse Response

Persistence: A gD mutant is attenuated in mice (Awasthi et al., 2008).
Efficacy: A gD mutant induces significant protection in mice from challenge with wild type HSV-1 (Awasthi et al., 2008).

3. Herpes simplex virus 1 gH mutant vaccine

a. Vaccine Ontology ID:

VO_0002971

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of gH

Type: Gene mutation
Description: This gH mutant is from Herpes simplex virus type 1 (Farrell et al., 1994).
Detailed Gene Information: Click here.

f. Immunization Route

Ear pinna

g. Mouse Response

Persistence: A gH mutant is attenuated in mice (Farrell et al., 1994).
Efficacy: A gH mutant induces significant protection in mice from challenge with wild type HSV-1 (Farrell et al., 1994).

4. Herpes simplex virus 1 TK mutant vaccine

a. Vaccine Ontology ID:

VO_0002973

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of TK

Type: Gene mutation
Description: This TK mutant is from human herpesvirus type 1 (Field and Wildy, 1978).
Detailed Gene Information: Click here.

f. Immunization Route

Intracerebral immunization

g. Mouse Response

Persistence: A TK mutant is attenuated in mice (Field and Wildy, 1978).
Efficacy: A TK mutant induces significant protection from challenge with wild type HSV-1 (Field and Wildy, 1978).

5. Herpes simplex virus 1 UL29 mutant vaccine

a. Vaccine Ontology ID:

VO_0002974

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of UL29

Type: Gene mutation
Description: This UL29 mutant is from human herpesvirus type 1 (Morrison and Knipe, 1994).
Detailed Gene Information: Click here.

f. Immunization Route

subcutaneous injection

g. Mouse Response

Persistence: A UL29 mutant is attenuated in mice (Morrison and Knipe, 1994).
Efficacy: A UL29 mutant induces significant protection from challenge with wild type HSV-1 (Morrison and Knipe, 1994).

6. Herpes Simplex Virus 2 DNA Vaccine encoding gD

a. Vaccine Ontology ID:

VO_0004522

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

pDNAVACC (Tirabassi et al., 2011)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccination Protocol: gD DNA vaccine or empty plasmid was administered intramuscularly on days 0 and 2. gD-liposomes or empty liposomes were administered 3 weeks after the DNA prime (50 μl total dose per mouse per time point in both nostrils) (Tirabassi et al., 2011).
Vaccine Immune Response Type: VO_0000286
Immune Response: The vaccine stimulated high titers of serum neutralising antibodies, a DNA priming dose dependent T helper type response, enhanced mucosal immune responses and potent protective immunity at the vaginal cavity, the portal of entry for the virus (Tirabassi et al., 2011).
Challenge Protocol: The clinical isolate, HSV-2 strain MS was grown and titered in Vero cells. LD50 was titrated in Balb/c mice prior to the challenge experiments. Five days prior to infection, mice were injected subcutaneously with 2 mg of medroxyprogesterone. On the day of infection, animals were anesthetised intraperitoneally with a ketamine/xylazine mixture and instilled intravaginally with a 20 μl suspension containing the indicated virus dose (Tirabassi et al., 2011).
Efficacy: The vaccine induced durable protection in mice, demonstrated by a 60% survival rate when lethal infections were performed 20 weeks after the immunisation primed with 0.5 μg of DNA vaccine (Tirabassi et al., 2011).

7. Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L

a. Vaccine Ontology ID:

VO_0004523

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

pCDNA3-CD40L (Sin et al., 2001)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccination Protocol: The quadriceps muscles of BALB/c mice were injected with 10–60 mg of pgD DNA constructs formulated in a final volume of 100 ml of phosphate-buffered saline and 0.25% bupi- vacaine-HCl, using a 28-gauge needle. Forty micrograms of CD40 and CD40L gene expression cassettes was mixed with pgD plasmid solution prior to injection (Sin et al., 2001).
Vaccine Immune Response Type: VO_0000286
Immune Response: When coinjected with CD40L plus pgD vaccines, a significant increase in Th cell-proliferative responses was observed. Specifically, CD40L drives immune responses toward a Th1 phenotype (Sin et al., 2001).
Challenge Protocol: After DNA injection, mice were challenged intravaginally with HSV-2 strain 186 with some modification. Before inoculating the virus, the intravaginal area was
swabbed with a cotton-tipped applicator soaked with 0.1 M NaOH solution and then cleared with dried cotton applicators (Sin et al., 2001).
Efficacy: When mice were immunized with gD plasmid DNA and then challenged with 4 LD50, 60% survival of gD plasmid-vaccinated animals was noted. When covaccinated with CD40L, 100% of the challenged animals survived (Sin et al., 2001).

8. Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2

a. Vaccine Ontology ID:

VO_0004521

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

VR1012 (Shlapobersky et al., 2012)

f. Immunization Route

Intravaginal injection

g. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Both FL and S forms of gD2 formulated with Vaxfectin showed significantly higher antibody titres, compared with gD2 alone (Shlapobersky et al., 2012).
Efficacy: At a high viral challenge, the 0.1 µg dose of FL gD2 Vaxfectin-formulated pDNA yielded 80 % survival. In addition, 40 % of mice vaccinated with adjuvanted FL pDNA had no detectable HSV-2 viral genomes in the dorsal root ganglia (Shlapobersky et al., 2012).

9. Herpes simplex virus 2 ICP0 mutant vaccine

a. Vaccine Ontology ID:

VO_0002972

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of ICP0

Type: Gene mutation
Description: This ICP0 mutant is from Human herpesvirus type 2 (Halford et al., 2011).
Detailed Gene Information: Click here.

f. Immunization Route

Vaginal immunization

g. Mouse Response

Persistence: An ICP0 mutant is attenuated in mice (Halford et al., 2011).
Efficacy: An ICP0 mutant induces protection in mice from challenge with wild type HSV-2 (Halford et al., 2011).
Host Gene Response of IgG
- Gene Response: Immunization with the live-attenuated HSV-2 0ΔNLS virus elicited a significant IgG antibody response directed against HSV-2's entry receptor, gD-2. gD-2 specific IgG antibodies were detected at levels significantly higher than levels detected in naive mice at day 50 after inoculation (Halford et al., 2011).
- Detailed Gene Information: Click here.

10. Herpes simplex virus DNA vaccine ∆gB-2 encoding gB

a. Vaccine Ontology ID:

VO_0004366

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse, guinea pig

e. Gene Engineering of UL27

Type: DNA vaccine construction
Description: Vector V1Jns expressed the hsV-2 gB gene (McClements et al., 1996).
Detailed Gene Information: Click here.

f. Vector:

V1Jns (McClements et al., 1996)

g. Immunization Route

Intraperitoneal injection (i.p.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: The DNA immunization has the capacity to elicit cell-mediated, as well as humoral immune responses. In addition, injection of mice showed that each construction induced neutralizing serum antibodies (McClements et al., 1996).
Efficacy: Immunized and control (saline-injected) mice were challenged by i.p. injection of HSV-2 and observed daily for survival. Significant protection from death was found for each dose tested (P< 0.01 for the 30, 10, and 3 ug groups, and P = 0.027 for the 1 ug group) (McClements et al., 1996).

11. Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis

a. Vaccine Ontology ID:

VO_0004370

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse, guinea pig

e. Antigen

gD and gB from HSV-2 strain Curtis (McClements et al., 1997)

f. Gene Engineering of gD

Type: DNA vaccine construction
Description: Vector V1Jns expressed HSV envelope glycoproteins D (gD) (McClements et al., 1997).
Detailed Gene Information: Click here.

g. Gene Engineering of UL27

Type: DNA vaccine construction
Description: Vector V1Jns expressed HSV envelope glycoprotein B (UL27) (McClements et al., 1997).
Detailed Gene Information: Click here.

h. Vector:

V1Jns (McClements et al., 1997)

i. Immunization Route

Intramuscular injection (i.m.)

j. Guinea pig Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Immunization with a plasmid expressing gB induced humoral immune responses and virus neutralization (McClements et al., 1997).
Efficacy: When the gB plasmid was combined with a plasmid expressing full-length gD, immunized guinea pigs developed humoral responses to both proteins and were also significantly protected from viral challenge. In addition, immunized animals were partially protected from genital herpes, exhibiting significantly reduced primary and subsequent recurrent disease (McClements et al., 1997).

12. Herpes simplex virus DNA vaccine gB-DNA encoding gB

a. Vaccine Ontology ID:

VO_0004368

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of UL27 from Herpes simplex virus type 1

Type: DNA vaccine construction
Description: This DNA vaccine encodes glycoprotein B (gB) (Manickan et al., 1997).
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccine Immune Response Type: VO_0000286
Efficacy: The majority of mice immunized with plasmid DNA encoding gB resisted challenge with 10 ID50 of virus (Manickan et al., 1997).

13. Herpes simplex virus DNA vaccine gBDNA encoding gB

a. Vaccine Ontology ID:

VO_0004369

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of UL27 from Herpes simplex virus type 1

Type: DNA vaccine construction
Description: This DNA vaccine expressed glycoprotein B of HSV (gBDNA) (Toka and Rouse, 2005).
Detailed Gene Information: Click here.

f. Vector:

pIL-15 (Toka and Rouse, 2005).

g. Immunization Route

intranasal immunization

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: pIL-15 generated memory CD8 T cell responses that were threefold higher and mainly maintained in the spleen, but high levels of immunoglobulin A antibodies were induced and maintained long-term in the vaginal mucosa (Toka and Rouse, 2005).
Efficacy: The enhanced immune responses ensuing from this strategy of immunization were protective upon lethal challenge with HSV-1. Five out of six mice survived after challenge (Toka and Rouse, 2005).

14. Herpes simplex virus DNA vaccine gD-2 encoding gD

a. Vaccine Ontology ID:

VO_0004365

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse, guinea pig

e. Gene Engineering of gD

Type: DNA vaccine construction
Description: Vector V1Jns expressed the HSV-2 gD gene (McClements et al., 1996).
Detailed Gene Information: Click here.

f. Vector:

V1Jns (McClements et al., 1996)

g. Immunization Route

Intraperitoneal injection (i.p.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: The DNA immunization has the capacity to elicit cell-mediated, as well as humoral immune responses. In addition, injection of mice showed that each construction induced neutralizing serum antibodies (McClements et al., 1996).
Efficacy: Immunized and control (saline-injected) mice were challenged by i.p. injection of HSV-2 and observed daily for survival. Significant protection from death (P< 0.001) was achieved for each dose. Eighty-two of eighty-six gD-2 DNA-immunized mice survived challenge (McClements et al., 1996).

15. Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27

a. Vaccine Ontology ID:

VO_0004367

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of ICP27

Type: DNA vaccine construction
Description: This DNA vaccine expresses infectious cell polypeptide 27(ICP-27) (Manickan et al., 1997).
Detailed Gene Information: Click here.

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: DC-delivered DNA appeared to be associated mainly with an increased Thi CD4 T cell response (Manickan et al., 1997).
Efficacy: The majority of mice immunized with plasmid DNA encoding ICP 27 resisted challenge with 10 ID50 of virus (Manickan et al., 1997).

16. Herpes simplex virus DNA vaccine pCI-gB encoding gB

a. Vaccine Ontology ID:

VO_0004412

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of gB

Type: DNA vaccine construction
Description: Vector pCI expressed glycoprotein B of herpes simplex virus type 1 (Hariharan et al., 1998).
Detailed Gene Information: Click here.

f. Vector:

pCI (Hariharan et al., 1998)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: A single intramuscular immunization of BALB/c mice with pSIN vectors expressing the glycoprotein B of herpes simplex virus type 1 induced a broad spectrum of immune responses, including virus-specific antibodies, cytotoxic T cells, and protection from lethal virus challenge in two different murine models (Hariharan et al., 1998).
Efficacy: 100% of the mice surviving the lethal i.p. McKrae challenge, demonstrating complete protection. None of the mice immunized with 100-μg doses of either negative control plasmid (pCI-HBVe or pSIN1.5-HBVe) survived (Hariharan et al., 1998).

17. Herpes simplex virus DNA vaccine pSIN-gB encoding gB

a. Vaccine Ontology ID:

VO_0004411

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of UL27 from Herpes simplex virus type 1

Type: DNA vaccine construction
Description: Vector Sindbis virus-based (pSIN vectors) expressed glycoprotein B of herpes simplex virus type 1 (Hariharan et al., 1998).
Detailed Gene Information: Click here.

f. Vector:

Sindbis virus-based (pSIN vectors) (Hariharan et al., 1998)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccine Immune Response Type: VO_0000286
Immune Response: A single intramuscular immunization of BALB/c mice with pSIN vectors expressing the glycoprotein B of herpes simplex virus type 1 induced a broad spectrum of immune responses, including virus-specific antibodies, cytotoxic T cells, and protection from lethal virus challenge in two different murine models (Hariharan et al., 1998).
Efficacy: 100% of the mice surviving the lethal i.p. McKrae challenge, demonstrating complete protection. None of the mice immunized with 100-μg doses of either negative control plasmid (pCI-HBVe or pSIN1.5-HBVe) survived (Hariharan et al., 1998).

18. Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP

a. Vaccine Ontology ID:

VO_0004520

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of UL27 from Herpes simplex virus type 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of UL44 from HSV-1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of US8

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of US7

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Vector:

VR-1055 (Osorio et al., 2004)

j. Immunization Route

Intramuscular injection (i.m.)

k. Mouse Response

Vaccination Protocol: The complete open reading frame for each of the five HSV-1 glycoproteins (gB, gC, gD, gE, and gI) was cloned into the VR-1055 expression vector and grown in bacteria. Plasmid DNA encoding each glycoprotein was purified on a cesium chloride gradient. In each experiment, 10 mice per group were inoculated intramuscularly (IM) into each quadriceps on days 0, 21, and 42 with a cocktail consisting of 10 μg of each cesium chloride–purified DNA (Osorio et al., 2004).
Vaccine Immune Response Type: VO_0000286
Immune Response: All immunized groups had significantly higher neutralizing antibody titers than mock-vaccinated mice (Osorio et al., 2004).
Challenge Protocol: Ocular challenge was performed 3 weeks after the final immunization. An inoculum of 2 × 105 or 2 × 106 pfu of HSV-1 strain McKrae in 5 μL tissue culture medium was placed in each eye without anesthesia and without corneal scarification, and the lid was gently rubbed for 30 seconds (Osorio et al., 2004).
Efficacy: In all vaccine groups, 10 of 10 (100%) of the mice survived, whereas only 15 of 70 (21%) mock groups showed similar survival patterns after ocular infection (Osorio et al., 2004).

19. Herpes simplex virus type 1 DNA vaccine encoding GC

a. Vaccine Ontology ID:

VO_0011408

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type 1 envelope glycoprotein C

e. Gene Engineering of UL44 from HSV-1

Type: DNA vaccine construction
Description: The HSV-1 KOS gC gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gC) (Nass et al., 1998).
Detailed Gene Information: Click here.

f. Vector:

pRc/CMV

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 10^4 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10^4 pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).

20. Herpes simplex virus type 1 DNA vaccine encoding GD

a. Vaccine Ontology ID:

VO_0011421

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type1 glycoprotein D

e. Gene Engineering of US5

Type: DNA vaccine construction
Description: Plasmid DNA encoding HSV-1 glycoprotein D1 (gD1) was constructed by insertion of the gD1 gene into pcDNA3 (Jamali et al., 2009).
Detailed Gene Information: Click here.

f. Vector:

pcDNA3

g. Immunization Route

Intradermal injection (i.d.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were immunized three times intra-dermally with 50 µg of pcDNA3 gD1 in a total volume of 100 µl on days 0, 21 and 42 (gD1 group). NLX (Sigma) was dissolved in 100 µl PBS containing 50 µg of the pcDNA3 gD1 construct at a concentration of 5 mg kg–1 and injected to each mouse with the same protocol, i.e. NLX was administered intra-dermally in combination with the pcDNA3 gD1 on days 0, 21 and 42 (NLX-gD1 group). PBS was injected according to the same protocol into the third group of mice as a negative control (PBS group). Finally, the last control group of mice was inoculated according to the same protocol with 100 µl of inoculums containing 10^5 plaque-forming units (pfu) of KOS strain virus (KOS group) (Jamali et al., 2009).
Challenge Protocol: Three weeks after the last immunization, mice were challenged with a low dose [four mouse lethal dose fifty percent (MLD50) = 1 x 10^5 pfu] or a high dose (10 MLD50 = 1 x 10^5 pfu) of wild-type virus. The mortality rate was followed for 2 weeks (Jamali et al., 2009).
Efficacy: BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 (Jamali et al., 2009).

21. Herpes simplex virus type 1 DNA vaccine encoding GE

a. Vaccine Ontology ID:

VO_0011423

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type 1 glycoprotein E

e. Gene Engineering of US8

Type: DNA vaccine construction
Description: The HSV-1 KOS gE gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gE) (Nass et al., 1998).
Detailed Gene Information: Click here.

f. Vector:

pRc/CMV

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 10^4 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10^4 pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).

22. Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21

a. Vaccine Ontology ID:

VO_0004519

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Immunization Route

Eye-drop immunization

f. Mouse Response

Vaccination Protocol: For the vaccination experiments, Balb/c mice were randomly divided into pRSC-group (mock plasmid), pRSC-gD group, pRSC-gD-IL-21 group and pRSC-gD-IL-21+ nanoparticles group in order. 12 mice per group were used routinely. In the nanoparticles group, 20 μl (40 μg DNA) of the nanoparticles containing DNA vaccine pRSC-gD-IL-21 were topically dropped into the eye of each mouse on days 0, 14 and 28. In other groups, each mouse was inoculated topically into the eye with 40 μg DNA vaccine pRSC-gD-IL-21 or pRSC-gD or mock plasmid in 20 μl PBS 3 times at two week intervals (Hu et al., 2011).
Vaccine Immune Response Type: VO_0000286
Immune Response: The nanoparticles containing DNA vaccine pRSC-gD-IL-21 induced mice to generate higher levels of specific neutralizing antibody, sIgA in tears, and IFN-γ, IL-4 in serum (Hu et al., 2011).
Challenge Protocol: Three weeks after the final immunization, 6 mice per group were sacrificed and used for detecting immune efficiency, and the other 6 mice were used for HSV-1 challenge experiments. Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (1.5 mg/0.15 ml) and the corneas of mice were scarified 10 times with 1 ml needle and the ocular mucosa of each eye were dropped with HSV-1 (10 μl of 5 × 106 plaque forming unit (PFU)/ml) (Hu et al., 2011).
Efficacy: On day 10 after viral challenge, there was no keratitis in the mouse of the pRSC-gD-IL-21+ nanoparticles group, demonstrating that the pRSC-gD-IL-21+ nanoparticles vaccine was efficient to inhibit HSK in a mouse model (Hu et al., 2011).

23. Herpes simplex virus type 2 DNA vaccine encoding GB

a. Vaccine Ontology ID:

VO_0011406

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type 2 glycoprotein B (UL27)

e. Gene Engineering of UL27

Type: DNA vaccine construction
Description: The plasmid DNA used for immunization was purified by polyethylene glycol precipitation. Briefly, the cellular proteins were precipitated with 1 volume of 7.5 M ammonium acetate. The supernatant was then precipitated with isopropanol, after which the plasmids were extracted three times with phenol-chloroform and then precipitated with pure ethanol. The DNA quality was then checked by electrophoresis in 1% agarose gel. Next, the concentration of the plasmid DNA was measured using a GeneQuant RNA/DNA calculator (Biochrom, Cambridge, UK). The amount of endotoxin was then determined using the Limulus amebocyte lysate (LAL) test (< 0.05 EU/µg) (Kim et al., 2009).
Detailed Gene Information: Click here.

f. Vector:

cytomegalovirus promoter (pCI)

g. Immunization Route

Intranasal

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of 5- to 6-week old female mice (n = 7) were co-immunized intranasally (i.n.) with 100 µg of pCIgB in the presence of β2-adrenergic agonist, salbutamol (10, 50, 100, and 200 µg). To examine the effect of plasmid DNA backbone (e.g. CpG motif), some of mice were immunized i.n. with 100 µg of the control vector (pCI-neo) in parallel. The i.n. immunization was performed three times at 7-day intervals (days 0, 7, and 14) by depositing pCIgB dissolved in a total volume of 20 µl of PBS (pH 7.2) containing the indicated dose of salbutamol onto the nares of deeply anesthetized mice (Kim et al., 2009).
Challenge Protocol: BALB/c mice were subcutaneously injected with Depo-Provera (DP) (Upjohn Co., Kalamazoo, MI) at 2 mg per mouse. Five days following the injection of DP, the mice were challenged intravaginally with 10^6 PFU of HSV-1 McKrae. The mice were examined daily for vaginal inflammation, neurological illness, and death (Kim et al., 2009).
Efficacy: The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection (Kim et al., 2009).

24. Herpes simplex virus type 2 DNA vaccine encoding ICP27

a. Vaccine Ontology ID:

VO_0011405

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type 2 transcriptional regulator ICP27

e. Gene Engineering of ICP27 from Herpes simplex virus type 2

Type: DNA vaccine construction
Description: The plasmid-encoding HSV-2 ICP27 was generated by inserting a PCR fragment incorporating the entire ICP27 gene (UL54) into pTarget (Promega, Madison, WI) (Haynes et al., 2006).
Detailed Gene Information: Click here.

f. Vector:

pTarget, and a plasmid vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT)

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Each immunization of 6–8-week-old female Balb/c mice consisted of a single PMED™ delivery to the ventral abdominal skin in which each delivery contained 0.5 mg of gold coated with a total of 0.5 μg of the DNA vaccine-DEI vector formulation. Two such “single shot” immunizations were administered 4 weeks apart and animals were sacrificed or challenged 2 weeks following the second immunization (Haynes et al., 2006).
Challenge Protocol: Anesthetized Balb/c mice were intranasally challenged with 30 μl of PBS containing approximately 50 LD50 (2 × 10^6 PFU) of HSV-2 strain MS. Mice were followed for 20 days after infection and scored for morbidity and mortality (Haynes et al., 2006).
Efficacy: Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality (Haynes et al., 2006).

25. Herpes simplex virus type 2 vaccine using phage displaying GG protein

a. Vaccine Ontology ID:

VO_0011420

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Antigen

Herpes simplex virus type 2 envelope glycoprotein G (US4)

e. Gene Engineering of US4

Type: Recombinant protein preparation
Description: Phage clones were isolated that express peptides that mimic single epitopes of the glycoprotein G of HSV-2, gG2 (Grabowska et al., 2000).
Detailed Gene Information: Click here.

f. Vector:

Filamentous phage

g. Immunization Route

Subcutaneous injection

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were obtained from a randomly bred, closed colony at the Sheffield University animal facility. Immunisations were administered subcutaneously at 2-week intervals. The dose given is the quantity of phage used per mouse per immunisation in a 200 ml volume of TBS. Prebleeds were obtained from a random selection of the mice prior to immunisation, and further bleeds were taken from all mice 2 weeks after each immunisation (Grabowska et al., 2000).
Challenge Protocol: Four weeks after the last immunisation, mice were challenged with 5±6 mouse lethal doses of HSV-2 (strain 333). Survival of the mice was monitored daily (Grabowska et al., 2000).
Efficacy: In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 (Grabowska et al., 2000).

26. HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70

a. Vaccine Ontology ID:

VO_0004578

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

HSV–2gD gene fragment and Tubercle bacillus Hsp70 gene (Fan and Yang, 2010)

f. Gene Engineering of gD

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pVAX (Fan and Yang, 2010)

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Vaccine Immune Response Type: VO_0003057
Immune Response: The IgG response in serum in vaccinated mice with pVAX–HSV–2gD and pVAX–HSV–2gD–Hsp70 differed significantly (P < 0.05) from those in immunized mice with pVAX and pVAX–Hsp70, which did not generate antibody levels above background. The highest IgG concentration was observed in serum of mice immunized with pVAX–HSV–2gD–Hsp70, which showed significant differences compared with the other three groups (P < 0.05) (Fan and Yang, 2010).
Efficacy: Eight of the animals (8/10) have survived in group pVAX–HSV–2gD–Hsp70. Only one survived in the pVAX and pVAX–Hsp70 groups (Fan and Yang, 2010).

27. HSV glycoproteins subunit vaccine

a. Vaccine Ontology ID:

VO_0004267

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

gB2t + gD2t (Burke et al., 1994)

e. Adjuvant:

VO ID: VO_0001302

f. Adjuvant:

VO ID: VO_0001301

g. Immunization Route

not specified

28. pRP-RSV-HSV-1-gB

a. Vaccine Ontology ID:

VO_0004723

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of gB

Type: Recombinant vector construction
Description: The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).
Detailed Gene Information: Click here.

f. Preparation

The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Vaccination Protocol: Mice were immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies (Manservigi et al., 1990).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Mice were challenged with HSV-1 or LV (Manservigi et al., 1990).
Efficacy: Mice immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies and were protected against HSV-1 lethal, latent, and recurrent infections (Manservigi et al., 1990).

29. rOka-gD2- HSV-2

a. Vaccine Ontology ID:

VO_0004710

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of gD

Type: Recombinant vector construction
Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
Detailed Gene Information: Click here.

f. Preparation

Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).

g. Immunization Route

Intramuscular injection (i.m.)

h. Guinea pig Response

Vaccination Protocol: The guinea pigs were inoculated with three doses of uninfected human fibroblasts, fibroblasts infected with ROka VZV, or fibroblasts infected with ROka-gD2 (Heineman et al., 1995).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: The guinea pigs were challenged intravaginally with HSV-2 (Heineman et al., 1995).
Efficacy: Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001). These experiments demonstrate that the Oka strain of VZV can be used as a live virus vector to protect animals from disease with a heterologous virus (Heineman et al., 1995).

V. References

1. Awasthi et al., 2008: Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine. 2008; 26(9); 1195-1203. [PubMed: 18243431].

2. Awasthi et al., 2011: Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. Journal of virology. 2011; 85(20); 10472-10486. [PubMed: 21813597].

3. Brittle et al., 2008: Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. Journal of virology. 2008; 82(17); 8431-8441. [PubMed: 18562543].

4. Burke et al., 1994: Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. The Journal of infectious diseases. 1994; 170(5); 1110-1119. [PubMed: 7963702].

5. Chlibek et al., 2013: Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. The Journal of infectious diseases. 2013; ; . [PubMed: 23904292].

6. Fan and Yang, 2010: Fan J, Yang H. Construction and immune response of HSV-2gD-Hsp70 DNA vaccine. Journal of dermatological science. 2010; 57(1); 64-66. [PubMed: 19942410].

7. Farrell et al., 1994: Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, Minson AC. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. Journal of virology. 1994; 68(2); 927-932. [PubMed: 8289395].

8. Field and Wildy, 1978: Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. The Journal of hygiene. 1978; 81(2); 267-277. [PubMed: 212476].

9. GlaxoSmithKline, 2013: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [http://clinicaltrials.gov/ct2/show/study/NCT01165177]

10. Goel et al., 2005: Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Frontiers in bioscience : a journal and virtual library. 2005; 10; 966-974. [PubMed: 15569635].

11. Grabowska et al., 2000: Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology. 2000; 269(1); 47-53. [PubMed: 10725197].

12. Halford et al., 2011: Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS one. 2011; 6(3); e17748. [PubMed: 21412438].

13. Hariharan et al., 1998: Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky TW Jr, Chang SM, Banks TA. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. Journal of virology. 1998; 72(2); 950-958. [PubMed: 9444987].

14. Haynes et al., 2006: Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine. 2006; 24(23); 5016-5026. [PubMed: 16621198].

15. Heineman et al., 1995: Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of virology. 1995; 69(12); 8109-8113. [PubMed: 7494331].

16. Hu et al., 2011: Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine. 2011; 29(7); 1455-1462. [PubMed: 21185849].

17. Huilan et al., 2010: Huilan Y, Cui Z, Jianyong F, Lei G, Wei Q. Construction of, and T-helper (Th)1/Th2 immune responses to, a herpes simplex virus type 2 glycoprotein D-cytotoxic T-lymphocyte epitope DNA vaccine. Clinical and experimental dermatology. 2010; ; . [PubMed: 20497188].

18. Jamali et al., 2009: Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, Soleimanjahi H, Motazakker M, Shahabi S. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. International immunology. 2009; 21(3); 217-225. [PubMed: 19174474].

19. Kim et al., 2009: Kim SB, Han YW, Rahman MM, Kim SJ, Yoo DJ, Kang SH, Kim K, Eo SK. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist. Experimental & molecular medicine. 2009; 41(11); 812-823. [PubMed: 19641376].

20. Manickan et al., 1997: Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. Journal of leukocyte biology. 1997; 61(2); 125-132. [PubMed: 9021916].

21. McClements et al., 1996: McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(21); 11414-11420. [PubMed: 8876149].

22. McClements et al., 1997: McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 1997; 15(8); 857-860. [PubMed: 9234533].

23. Mester et al., 1999: Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine. 1999; 18(9-10); 875-883. [PubMed: 10580201].

24. Morrison and Knipe, 1994: Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. Journal of virology. 1994; 68(2); 689-696. [PubMed: 8289372].

25. Nass et al., 1998: Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. The Journal of infectious diseases. 1998; 178(3); 611-617. [PubMed: 9728527].

26. Orr et al., 2007: Orr MT, Orgun NN, Wilson CB, Way SS. Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. Journal of immunology (Baltimore, Md. : 1950). 2007; 178(8); 4731-4735. [PubMed: 17404252].

27. Osorio et al., 2004: Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Investigative ophthalmology & visual science. 2004; 45(2); 506-514. [PubMed: 14744892].

28. Shlapobersky et al., 2012: Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. The Journal of general virology. 2012; 93(Pt 6); 1305-1315. [PubMed: 22398318].

29. Sin et al., 2001: Sin JI, Kim JJ, Zhang D, Weiner DB. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Human gene therapy. 2001; 12(9); 1091-1102. [PubMed: 11399230].

30. Tirabassi et al., 2011: Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine. 2011; 29(5); 1090-1098. [PubMed: 21134447].

31. Toka and Rouse, 2005: Toka FN, Rouse BT. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of leukocyte biology. 2005; 78(1); 178-186. [PubMed: 15817700].

32. Veselenak et al., 2012: Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfectin(Â®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine. 2012; 30(49); 7046-7051. [PubMed: 23041125].

33. Wiki: Herpes simplex virus: Herpes simplex virus [http://en.wikipedia.org/wiki/Herpes_simplex_virus]